Latent Variable Approaches for Understanding Heterogeneity in Depression: A Dissertation by Ulbricht, Christine M.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2015-04-23 
Latent Variable Approaches for Understanding Heterogeneity in 
Depression: A Dissertation 
Christine M. Ulbricht 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Clinical Epidemiology Commons, Health Services Research Commons, Mental Disorders 
Commons, Psychiatric and Mental Health Commons, Psychiatry Commons, and the Statistics and 
Probability Commons 
Repository Citation 
Ulbricht CM. (2015). Latent Variable Approaches for Understanding Heterogeneity in Depression: A 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/M2FG68. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/774 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 
 
 
 
 
 
 
LATENT VARIABLE APPROACHES FOR UNDERSTANDING HETEROGENEITY 
IN DEPRESSION 
 
 
 
 
 
A Dissertation Presented 
 
 
By 
 
 
CHRISTINE MARIE ULBRICHT 
 
 
 
 
 
Submitted to the Faculty of the 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
 
APRIL 23, 2015 
 
CLINICAL AND POPULATION HEALTH RESEARCH 
  
LATENT VARIABLE APPROACHES FOR UNDERSTANDING HETEROGENEITY 
IN DEPRESSION 
 
 
A Dissertation Presented 
By 
 
CHRISTINE MARIE ULBRICHT 
 
 
The signatures of the Dissertation Defense Committee signify 
completion and approval as to style and content of the Dissertation 
 
________________________________________________________________ 
Kate L. Lapane, Ph.D., Thesis Advisor 
 
________________________________________________________________ 
Robert K. Heinssen, Ph.D., ABPP, Member of Committee 
 
________________________________________________________________ 
Sharina D. Person, Ph.D., Member of Committee 
 
________________________________________________________________ 
Anthony J. Rothschild, M.D., Member of Committee 
 
 
The signature of the Chair of the Committee signifies that the written dissertation meets 
the requirements of the Dissertation Committee 
 
________________________________________________________________ 
Eric Mick, Sc.D., Chair of Committee 
 
 
The signature of the Dean of the Graduate School of Biomedical Sciences signifies that 
the student has met all graduation requirements of the school. 
 
________________________________________________________________ 
Anthony Carruthers, Ph.D. 
Dean of the Graduate School of Biomedical Sciences 
 
Clinical and Population Health Research 
 
April 23, 2015
iii 
 
 
ACKNOWLEDGEMENTS 
This work could not have been completed without the support and guidance of 
many people, to whom I would like to express my gratitude. 
I would like to first profusely thank my mentor and program director Kate L. 
Lapane, PhD, for her unwavering support throughout the program and for her patience 
with me and these methods.  
I am also grateful to my dissertation committee of Robert K. Heinssen, PhD, 
ABPP; Eric Mick, ScD; Sharina Person, PhD; and Anthony J. Rothschild, MD. Their 
time, advice, and support throughout this process were invaluable. 
I never would have made it to this point without the mentoring and life coaching 
of my former colleagues Jean Baum and Joanne Severe. Their personal and professional 
accomplishments continually inspire me. Their sage wisdom is always appreciated, 
especially when delivered over a glass of wine. 
I am indebted to the STAR*D participants and staff for their tremendous 
contribution to advancing the treatment of major depression and without whom this 
dissertation would not have been possible.   
I have also benefitted tremendously from the support of the faculty and staff of 
the Clinical and Population Health Research Program/Department of Quantitative Health 
Sciences, especially: Kelley Baron; Terry Field, DSc; Stephenie Lemon, PhD; Sandy 
Stankus; and Mayra S. Tisminetzky, MD, PhD. Many thanks are also owed to all of my 
fellow CPHR students but especially to my cohort members for making sure I did not 
iv 
 
 
quit at any point in the last four years: Carol Curtin, MSW (very soon to be PhD); Dan 
Frendl (soon to be MD/PhD); Camilla Pimentel, PhD; and Mollie Wood, PhD. 
 Last but definitely not least, I am beyond grateful to my friends and family, 
especially: Karl Anderson,  Billie Giannone, Christopher Richards, Kate Ryan, and 
Kasim Te. Thank you so much for your unconditional support and for making me laugh 
for all of these years. 
  
v 
 
 
ABSTRACT  
Background: Major depression is one of the most prevalent, disabling, and costly 
illnesses worldwide. Despite a 400% increase in antidepressant medication use since 
1988, fewer than half of treated depression patients experience a clinically meaningful 
reduction in symptoms and uncertainty exists regarding how to successfully obtain 
symptom remission. Identifying homogenous subgroups based on clinically observable 
characteristics could improve the ability to efficiently predict who will benefit from 
which treatments.  
Methods: Latent class analysis and latent transition analysis (LTA) were applied to data 
from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study to 
explore how to efficiently identify subgroups comprised of the multiple dimensions of 
depression and examine changes in subgroup membership during treatment. The specific 
aims of this dissertation were to: 1) evaluate latent depression subgroups for men and 
women prior to antidepressant treatment; 2) examine transitions in these subgroups over 
12 weeks of citalopram treatment; and 3) examine differences in functional impairment 
between women’s depression subgroups throughout treatment. 
Results: Four subgroups of depression were identified for men and women throughout 
this work. Men’s subgroups were distinguished by depression severity and psychomotor 
agitation and retardation. Severity, appetite changes, insomnia, and psychomotor 
disturbances characterized women’s subgroups. Psychiatric comorbidities, especially 
anxiety disorders, were related to increased odds of membership in baseline moderate and 
severe depression subgroups for men and women. After 12 weeks of citalopram 
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treatment, depression severity and psychomotor agitation were related to men’s chances 
of improving. Severity and appetite changes were related to women’s likelihood of 
improving during treatment. When functional impairment was incorporated in LTA 
models for women, baseline functional impairment levels were related to both depression 
subgroups at baseline and chances of moving to a different depression subgroup after 
treatment. 
Conclusion: Depression severity, psychomotor disturbances, appetite changes, and 
insomnia distinguished depression subgroups in STAR*D. Gender, functional 
impairment, comorbid psychiatric disorders, and likelihood of transitioning to subgroups 
characterized by symptom improvement differed between these subgroups. The results of 
this work highlight how relying solely on summary symptom rating scale scores during 
treatment obscures changes in depression that might be informative for improving 
treatment response. 
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CHAPTER I 
 INTRODUCTION 
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Major Depression 
 
 Major depression is one of the most prevalent and burdensome diseases 
worldwide,1,2 conferring substantial disability, morbidity, and mortality. The 12-month 
prevalence of major depression in the United States has been estimated to be 7%2  and 
lifetime prevalence of major depression has been estimated to range from 15-17%.3  In 
2010, more than 15 million adults in the U.S. had experienced major depression in the 
past year.4 The incremental burden of individuals with major depression in the U.S. alone 
was $210.5 billion in 2010.4 This includes treatment costs, losses from absenteeism and 
lack of productivity, and lifetime earnings lost due to suicide. Depression is a leading 
cause of disease burden throughout the world and is anticipated to be the leading cause of 
disability by 2030.5 The symptoms of depression have been shown to impair ability to 
function in work, household, relationship, and social roles in more than 50% of people 
with major depression. Beyond suicide deaths, depression is also associated with 
increased mortality from related chronic comorbid medical conditions. 
 Given the burden of major depression, effective treatment is necessary but there is 
limited information on how to best treat people so that symptom remission and improved 
functioning are achieved.6 Despite a 400% increase in the use of antidepressant 
medication between 1988-1994 and 2005-2008,7 only 51.7% people with depression 
receive any treatment.8 Of the people who do receive treatment, fewer than half 
experience a clinically meaningful reduction in symptoms.6,9 Providing effective 
treatment in a timely manner after treatment initiation is critical since patients tend to not 
return for treatment if response to initial treatment is poor. Half of people who start 
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antidepressant treatment do not receive follow-up care.10 This occurs despite the high 
likelihood that a good response may eventually be achieved by switching treatments.11  
 The lack of treatment response in depression might be partially explained by the 
non-specific symptomatology and variability in severity and trajectory of the disease. 
More than 1,400 combinations of DSM criteria symptoms are possible12 and considerable 
differences in illness course, prominent symptoms, and treatment response have been 
observed.13 Depression presents differently by a number of factors.13–16 In particular, 
gender differences have been documented in depression rates, severity, course, risk 
factors, and symptoms, with women experiencing depression more often and more 
severely than men.17–20 Women also seem to be more likely to experience somatic, 
atypical, and anxiety symptoms.21–23 Additionally, more women than men experience a 
major depressive episode with severe functional impairment.17 When men with 
depression are affected by functional impairment, the domains in which functioning is 
impaired also appear to differ by gender.24  
Although the presence of heterogeneity is well-established in depression, how to 
best delineate subgroups of people who share similar features is still debatable.25 
Depression subtypes based on symptom patterns have been proposed but the clinical 
utility of these categorizations is unclear. When participants in the International Study to 
Predict Optimized Treatment in Depression (iSPOT-D) and Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) trials were classified post-hoc into the 
classic melancholic, anxious, and atypical subtypes, a quarter of iSPOT-D and a third of 
STAR*D participants did not belong to any subtype.26 Among those who could be 
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classified, 48% in iSPOT-D and 39% in STAR*D met criteria for more than one subtype. 
Furthermore, the extent to which these subtypes or even individual symptoms change 
over time is uncertain. Identifying distinct homogenous subgroups based on clinically 
observable characteristics could eventually improve the ability to predict who will benefit 
from which treatments.11,27,28 It has also been seen that individual symptoms29,30 and 
subtypes31 can change throughout depressive episodes but few studies have been 
conducted and treatment has rarely been considered. Research about the longitudinal 
stability of subtypes, including transitions between subtypes during treatment, could 
ultimately inform efforts to address depression heterogeneity in personalizing treatment 
strategies, a goal of precision medicine and the National Institute of Mental Health’s 
Research Domain Criteria initiative.32 
Specific Aims 
This dissertation explored using latent class analysis (LCA) and latent transition 
analysis (LTA) to efficiently identify subgroups comprised of the multiple dimensions of 
depression and examine changes in subgroup membership during the first level of the 
STAR*D study, during which participants received the antidepressant citalopram. The 
specific aims of this dissertation were as follows. 
Aim 1. Evaluate baseline latent depression classes:   
 Examine underlying depression classes based on clusters of depression symptoms. 
 Evaluate gender differences in these classes. 
 Identify baseline correlates of class membership.   
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Aim 2. Examine transitions in latent depression classes over 12 weeks of treatment with 
citalopram: 
 Characterize patterns of depression symptoms during 12 weeks of treatment. 
 Examine changes in the descriptive nature of each subgroup and how participants 
move between subgroups. 
 Examine gender differences in these subgroups and transitions. 
Aim 3. Examine the association between functional impairment and latent depression 
statuses in women: 
 Characterize the association between functional impairment and major depression 
subgroups at baseline. 
 Characterize changes in depression subgroups by level of functional impairment at 
the end of 12 weeks of citalopram treatment. 
Data Source and Study Population 
We used a publicly available de-identified dataset from STAR*D, the largest and 
longest community-based depression treatment trial conducted to date, for this 
dissertation. STAR*D was a pragmatic clinical trial originally designed to assess the 
effectiveness of a variety of treatments for moderate-to-severe nonpsychotic depression.22 
In order to best capture real-world clinical practice, a variety of clinical settings 
throughout the U.S. were included and broad eligibility criteria were employed. Adults 
with major depression who were seeking treatment for their depression were eligible to 
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participate and 4,041 adults were enrolled from 18 primary care and 23 outpatient 
psychiatric sites between July 2001 and April 2004.  
In level 1 of STAR*D, all participants received citalopram for 12 to 14 weeks. 
Study visits were recommended at weeks 0, 2, 4, 6, 9, and 12, with an additional visit at 
week 14 for participants who experienced response or remission only at week 12. The 
main outcome measure was remission of depression symptoms and was defined as a 
score at study exit on the 17-item Hamilton Rating Scale of Depression (HRSD) of ≤ 7 or 
last observed 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16) 
score of ≤ 5.33 The secondary outcome was response, defined as at least 50% reduction in 
QIDS-SR16 baseline score. Those who achieved symptom remission could continue on 
citalopram for up to 12 months of follow-up while those with partial or no response could 
continue to subsequent randomized treatment levels. Approximately 28% of participants 
achieved remission as defined by the HRSD score and 47% of participants achieved 
response.33  
In level 1, all participants received citalopram. In level 2, those who did not 
respond to citalopram in level 1 had the option of augmenting citalopram or to be 
randomly assigned to switch to sertraline, bupropion-SR, or venlafaxine-XR. 
Psychotherapy was also a treatment option. If remission was not achieved during this 
phase, participants could continue on to level 3 where they could choose to be randomly 
assigned to mirtazapine or nortriptyline. In level 4, participants who did not become 
symptom-free in level 3 could switch to be randomly assigned to receive tranylcypromine 
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or venlafaxine-XR with mirtazpine. Approximately half of the participants achieved 
remission after two levels of treatment.9 
Data from level 1 was used for this dissertation. The original STAR*D 
investigators defined an evaluable sample of study participants as the 2,876 participants 
who had an HRSD score of at least 14 at baseline and had at least one post-baseline 
visit.33 This evaluable sample served as the basis of the sample eligible for the analyses of 
this dissertation. For the LCA at baseline in Aim 1, men and women were included if 
they were not missing all QID-SR16 items at baseline and were not missing baseline 
covariates of age, race/ethnicity, and psychiatry comorbidity. This resulted in a sample of 
2,772 participants. In Aim 2, only complete cases were used for the LTA model of 
baseline and week 12 visits. Participants must have completed study visits at baseline and 
week 12 and could not be missing all QIDS-SR16 items at these visits. The sample was 
thus comprised of 1,142 participants. The LTA models for Aim 3 included only women 
who had completed the QIDS-SR16 and the Work and Social Adjustment Scale at 
baseline and the QIDS-SR16 at week 12, resulting in a sample of 755 women. 
Analytic Methods 
Latent Class Analysis 
Aim 1 was accomplished by conducting an LCA to examine subgroups of 
depression at baseline in STAR*D. LCA models are finite mixture models that assume 
that there are mutually exclusive and exhaustive classes of individuals within a 
population that can be distinguished by values of an unobserved categorical variable.34 
This unobserved latent variable and resulting subgroups are derived from indicator 
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variables of observable phenomenon such as depression symptoms. The observed 
indicator variables are considered to be a function of the latent variable and error.   
Unlike traditional variable-centered methods of subgroup analysis, LCA accommodates a 
large amount of information to organize people into homogenous subgroups and thus has 
the potential to efficiently identify subgroups comprised of the many dimensions of major 
depression.35 In Aim 1, the latent depression variable was based on patterns of observed 
depression symptoms and known correlates of depression course were examined for each 
latent class in LCA models with covariates. 
LCA estimates two sets of parameters: latent class membership prevalences (γ) 
and item-response probabilities (ρ). Individuals have a probability of membership in each 
of the latent classes but true class membership is unknown and inferred from response 
patterns of the observed depression symptoms.34 The latent class membership prevalence 
is the probability of membership in that particular class. The item-response probabilities 
represent the relationship between each indicator variable and each latent class by 
identifying the response patterns of the observed characteristics that define each latent 
class.34 Item-response probabilities approaching 0 or 1 indicate a strong relationship 
between the observed indicator variable and the latent variable, meaning that the 
particular response can be determined with a high degree of certainty conditional on 
latent class membership. 
Figure 1.1 shows the overview of the LCA model that was used in Aim 1.36 The 
latent depression variable was based on the DSM-IV symptoms of major depression as 
measured by the QIDS-SR16. Gender was also considered as a grouping variable (model 
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not shown). Covariates of depression included age, race, and presence of comorbid 
psychiatric disorders such as generalized anxiety disorder and post-traumatic stress 
disorder. The overall model is:  
𝑃(𝐘 = 𝐲|X = 𝑥) = ∑ 𝛾𝑐 (𝑥) ∏ ∏ 𝜌𝑗,𝑟𝑗|𝑐
𝐼(𝑦𝑗=𝑟𝑗),
𝑅𝑗
𝑟𝑗=1
𝐽
𝑗=1
𝐶
𝑐=1  where yj is item j of the set of 
indicator variables y (e.g., early morning insomnia, sad mood, impaired concentration, 
etc.); rj is the response to item j; X is a covariate (e.g., age); and c is the latent depression 
subgroup.  𝛾𝑐(𝑥) is a logistic regression model of the probability of membership in latent 
depression class c = 
 𝑃(𝐿 = 𝑐|X = 𝑥) =
𝑒𝛽0𝑐+ 𝛽1𝑐𝐴𝑔𝑒+ 𝛽2𝑐𝑅𝑎𝑐𝑒+𝛽3𝑐𝑃𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑐𝐶𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑦
1+∑ 𝑒𝛽0𝑐+ 𝛽1𝑐𝐴𝑔𝑒+ 𝛽2𝑐𝑅𝑎𝑐𝑒+𝛽3𝑐𝑃𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑐𝐶𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑦𝐶−1
𝑐=1́
.34,35 
Basic models without covariates or a grouping variable were first fit in order to 
gain an understanding of the overall latent structure and the appropriate number of 
classes. These models were fit with numbers of classes that varied from two to seven. 
The G2 likelihood-ratio statistic, Akaike Information Criterion, Bayesian Information 
Criterion, solution stability, and interpretability of competing solutions were considered 
when selecting the model with the optimal number of latent classes.34 After this basic 
model was determined, gender was considered as a grouping variable. A multiple-group 
LCA permits the exploration of measurement invariance to see if the latent construct is 
the same across the groups. This approach allows for gender-specific estimation of latent 
class membership probabilities, item-response probabilities, and predictors of latent class 
membership. By considering gender as a grouping variable, it was possible to evaluate 
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two areas: 1) if men and women experience the same depression subgroups; and 2) if so, 
if the prevalence of each subgroup is similar in men and women.  
Measurement invariance between men and women was tested to see if the latent 
construct of depression was the same for men and women. If there is measurement 
invariance in the LCA, the number of classes and item-response probabilities will be the 
same across groups, indicating that the qualitative understanding of the depression 
symptoms characterizing the latent classes is the same between groups.34 Measurement 
invariance was examined with the G2 likelihood-ratio difference test to determine if the 
item-response probabilities differ in two nested models of the dichotomous QIDS-SR16 
indicators: a multiple-group model with all the prevalence and item-response probability 
parameters free to vary by gender and a multiple-group model with the item-response 
probabilities constrained to be equal between men and women.34 Beyond the results of 
the difference G2 test, we considered the principle of parsimony and the interpretability of 
the latent classes, especially in terms of clinically meaningful differences in the item-
response probabilities. 
After measurement invariance of the item-response probabilities was tested, the 
equivalence of the latent class prevalences across men and women was examined with 
the difference G2 test in a similar manner as measurement invariance. Two nested models 
were compared: a model where women’s and men’s item-response probabilities were 
constrained to be equal but latent class prevalences were allowed to vary and a model in 
which the item-response probabilities and latent class prevalences were constrained to be 
equal across the genders.34 After the equivalence of the latent class prevalences was 
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tested, covariates were added to the multiple-groups model using multinomial logistic 
regression. When covariates are added to the LCA model, the resulting odds ratios are the 
difference in odds of membership in the reference class compared to the other classes for 
individuals endorsing a particular covariate. Covariates were initially added individually 
to the LCA model with gender as a grouping variable and then a model adjusted for all 
the covariates was fit. An LCA model with covariates was used instead of the “classify-
analyze” approach of using posterior probabilities to assign individuals to their most 
likely latent class in order to traditionally analyze characteristics of the classes with 
descriptive statistics. This was done because the classify-analyze approach does not 
accommodate the uncertainty in classification in LCA and can thus introduce 
classification error.35  
Latent Transition Analysis 
Aims 2 and 3 employed LTA to examine changes in the latent depression classes 
over the 12 weeks of STAR*D level 1. LTA is the longitudinal extension of LCA. In 
LTA, “statuses” are analogous to “classes” in LCA. This distinction emphasizes that the 
statuses can be temporary states and people’s membership in these statuses can change.34 
As in LCA, LTA models latent status prevalences and item-response probabilities. Unlike 
LCA, LTA also estimates transition probabilities. These transition probabilities convey 
how changes occur between the statuses over time, demonstrating the incidence of 
transitioning to a latent status conditional on membership in an earlier status.  
In Aims 2 and 3, LTA models were fit to determine the probabilities for 
individual participants belonging to a particular depression subgroup at week 12 given 
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the individual’s depression subgroup membership at baseline (Figure 1.2).37 The basic 
LTA model for latent depression statuses at baseline and week 12 is: 
 𝑃(𝐘 = 𝐲) =  ∑ ∑ 𝛿𝑠1𝜏𝑠2|𝑠1 ∏ ∏ ∏ 𝜌𝑗,𝑟𝑗,𝑡|𝑠𝑡
𝐼(𝑦𝑗,𝑡=𝑟𝑗,𝑡)𝑅𝑗
𝑟𝑗,𝑡=1
𝐽
𝑗=1
2
𝑡=1
𝑆
𝑠2=1
𝑆
𝑠1=1 ,  
where 𝛿𝑠1 is the probability of membership in latent depression status s1 at baseline; 
𝜏𝑠2|𝑠1 is the probability of transitioning to latent status s2 at week 12 conditional on 
membership in latent status s1 at baseline; and 𝜌𝑡,𝑗,𝑟𝑗𝑡|𝑠𝑡  is the probability of response rj,t 
to item j at time t, conditional on membership in latent class st at time t.
34 In LTA, 
measurement invariance can exist across groups and/or across times. As was done in the 
LCA for Aim 1, measurement invariance was tested in nested models with the G2 
difference likelihood ratio test. In Aim 2, measurement invariance between men and 
women and between time points was examined. In Aim 3, measurement invariance was 
tested between women’s functional impairment groups and between time points.  
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Figure 1.1: Overview of the latent class analysis model to examine baseline subtypes of 
depression in STAR*D level 1 
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Figure 1.2: Overview of the latent transition analysis model to examine changes in 
depression subtype in STAR*D level 1 
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CHAPTER II 
SUBGROUPS OF DEPRESSION IN THE SEQUENCED TREATMENT 
ALTERNATIVES TO RELIEVE DEPRESSION (STAR*D) STUDY - A LATENT 
CLASS ANALYSIS 
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Abstract 
Objective: The objective of this study was to characterize latent classes of depression by 
symptoms, evaluate gender differences in these classes, and examine correlates of each 
class. 
Method: Latent class analysis was applied to baseline data from 2,772 participants in 
level 1 of the Sequenced Treatment Alternatives to Relieve Depression trial. Items from 
the Quick Inventory of Depressive Symptomatology were used as indicators. 
Multinomial logistic models identified correlates of latent classes (adjusted odds ratios 
(aOR) and 95% confidence intervals (CI)). 
Results: Four latent classes were identified: Mild (men: 37%, women: 27%), Moderate 
(men: 24%, women 21%), Severe with Increased Appetite (men: 13%, women: 22%), 
and Severe with Insomnia (men: 26%, women: 31%). Comorbid generalized anxiety 
disorder (aORwomen: 1.74; 95% CI: 1.06-2.85), bulimia (aORwomen: 5.21; 95% CI: 3.16-
8.59; aORmen: 12.29; 95% CI: 5.28-28.6), and social phobia (aORwomen: 3.68; 95% CI: 
2.36-5.75; aORmen: 3.22; 95% CI: 1.71-6.06) were correlated with Severe with Increased 
Appetite. Generalized anxiety disorder (aORwomen: 2.91; 95% CI: 1.91-4.41; aORmen: 
2.07; 95% CI: 1.24-3.46), post-traumatic stress disorder (aORwomen: 2.30; 95% CI: 1.51-
3.51; aORmen: 2.00; 95% CI: 1.24-3.24), and social phobia (aORwomen: 2.41; 95% CI: 
1.60-3.63) were correlated with Severe with Insomnia.  
Conclusions: Insomnia and increased appetite distinguished latent classes. Gender, 
anxiety disorders and other psychiatric comorbidities also differed between these classes. 
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These results suggest that sleep disturbances, appetite changes, and other mental 
disorders may play a role in the etiology of depression. 
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Introduction 
Major depression is one of the most prevalent, disabling, and costly illnesses 
worldwide.1,2 Despite a 400% increase in antidepressant medication use since 1988, the 
prevalence of depression remains around 7% for adults in the United States.7,17,38 Fewer 
than half of treated depression patients experience a clinically meaningful reduction in 
symptoms and uncertainty exists regarding how to successfully obtain symptom 
remission.6,9 Understanding this heterogeneity is necessary to identify predictors of 
response and ultimately improve the treatments and services available for depression.32  
How to delineate subgroups of people who respond differently to antidepressants 
is debatable.25 The heterogeneity is likely partially explained by the non-specific 
symptomatology and variability in severity and trajectory of depression. Depression 
presents differently by age, gender, race and ethnicity, and psychiatric comorbidities.13,15–
17 Numerous depression subtypes have been proposed but lack of clinical utility limits 
adoption.39 Identifying homogenous subgroups based on clinically observable 
characteristics could improve the ability to efficiently predict who will benefit from 
which treatments.11,27,28  
Latent class analysis (LCA) is a person-centered analytic approach which can be 
used to efficiently identify subgroups comprised of the multiple dimensions of 
depression.35 LCA models assume mutually exclusive and exhaustive classes of 
individuals within a population differentiated by values of an unobserved categorical 
latent variable.34 This latent variable and resulting classes are based on observed indicator 
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variables, such as depression symptoms. Individuals have a probability of membership in 
each of the latent classes, inferred from response patterns of indicator variables.34  
We sought to evaluate the extent to which latent classes based on depression 
symptoms could be identified using LCA. Data were used from level 1 of the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) trial, the largest community-
based study of major depression.33 STAR*D provides a unique opportunity to study 
patients who would have been excluded from most other studies.40,41 The objectives were 
to: 1) examine underlying depression classes based on patterns of depression symptoms; 
2) evaluate gender differences in latent depression classes; and 3) identify correlates of 
the depression classes.   
Methods 
Study Participants  
We used a de-identified dataset from STAR*D, a pragmatic clinical trial to assess 
the effectiveness of a variety of treatments for moderate-to-severe nonpsychotic 
depression.42 From July 2001-April 2004, 4,041 treatment-seeking patients were enrolled 
from 18 primary care and 23 outpatient psychiatric sites.43,44 The open-label, unblinded 
treatment protocol for level 1 allowed for flexible dosing of citalopram for 14 weeks.33 
Approximately 30% of participants achieved remission (primary endpoint: 17-item 
Hamilton Rating Scale of Depression (HRSD) of ≤ 7 or last observed 16-item Quick 
Inventory of Depressive Symptomatology (QIDS-SR16) score of ≤ 5) and 47% achieved 
response (secondary outcome: ≥ 50% reduction in QIDS-SR16 baseline score) by the end 
of level 1.33 
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LCA employs full information maximum likelihood for missing data on 
individual indicator variables such as the QIDS-SR16 items but requires complete case 
analysis for missing covariates. Of the evaluable sample (participants with HRSD ≥ 14 at 
baseline and ≥ one post-baseline visit, n= 2,876),45 15 participants were excluded because 
they were missing all QIDS-SR16 indicator items at baseline. An additional 89 
participants were excluded because they were missing the covariates of interest, resulting 
in a sample of 2,772 participants for this analysis. The University of Massachusetts 
Medical School Institutional Review Board determined that this secondary analysis was 
not human subject research. 
Measures 
Indicators of Latent Class Membership 
The 16 baseline QIDS-SR16 items were the indicator variables from which the 
latent class construct was inferred: sad mood, impaired concentration, self-criticism, 
suicidal ideation, lack of general interest, fatigue, sleep disturbances, appetite and weight 
changes, and psychomotor agitation/retardation.46 Items pertain to experiences in the past 
seven days, except for weight change (previous two weeks).  Item scores ranged from 0-
3, with scores ≥ 2 indicating the symptom met the DSM-IV depression threshold.44 All 
items were dichotomized (≤ 1: absence; ≥2: presence of a symptom).  Although the 
QIDS-SR16  instructions specify that only one item on decreased or increased appetite 
should be completed, these items were included as separate indicators to capture the 
direction of change. Weight changes were also treated this way. 
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Consideration of Gender in the LCA 
Gender differences occur in depression rates, severity, course, risk factors, and 
symptoms, with women experiencing depression more often and more severely than 
men.17–20 We did not a priori assume that men and women would have the same subtypes 
of depression. Instead, we evaluated: 1) if men and women experienced the same types of 
depression; and 2) gender differences in class prevalences. 
Correlates of Depression Class Membership 
We considered sociodemographic and clinical variables as correlates of 
depression class membership. Baseline age (<45 years versus ≥ 45 years), race, and 
psychiatric comorbidities were considered because these are previously identified 
demographic and clinical predictors of depression subtypes.47 Comorbid DSM-IV 
conditions were assessed at baseline with the Psychiatric Diagnostic Screening 
Questionnaire (PDSQ),48 which screens for 13 mood, anxiety, eating, substance use, and 
somatoform disorders.49 A threshold of 90% specificity was used to determine the 
presence of a disorder.50 We examined comorbid post-traumatic stress disorder (PTSD), 
social phobia, generalized anxiety disorder (GAD), and bulimia because the prevalence 
of each of these was ≥ 10%.  We created one variable that defined other psychiatric 
comorbidity as conditions occurring with low frequency, including obsessive-compulsive 
disorder (OCD), panic disorder, psychosis, agoraphobia, alcohol abuse/dependence, drug 
abuse/dependence, somatization, and/or hypochondriasis. 
 
 
22 
 
 
Statistical Analysis 
There were three analytic phases: 1) describing the sample and developing the 
LCA model; 2) evaluating gender differences in depression classes; and 3) evaluating 
class correlates. First, summary statistics of gender differences in baseline demographic 
and clinical characteristics were calculated using t-tests and chi-square tests as 
appropriate. We then constructed LCA models with numbers of classes varying from one 
to seven. Basic models without grouping variables and covariates were fit first to obtain a 
general understanding of the structure of the classes. These models were examined for fit, 
parsimony, interpretability, and sparseness of the indicator variables.34 Fit was assessed 
with Akaike information criterion (AIC)51 and Bayesian information criterion (BIC)52 
information criteria statistics.  
Second, after the optimal number of latent classes was selected for the basic 
model, models with gender as a grouping variable were examined to see if the number of 
latent classes was identical between men and women.  We explored measurement 
invariance using the difference G2 likelihood ratio test to see if the item-response 
probabilities, and thus the qualitative nature of the latent construct, were the same by 
gender.34 This test was used to determine if the item-response probabilities differed in 
two nested models of the QIDS-SR16 indicators: 1) a multiple-group model with all the 
prevalence and item-response probability parameters free to vary by gender; and 2) a 
multiple-group model with the item-response probabilities constrained to be equal 
between men and women.34 We considered parsimony and the interpretability of the 
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latent classes, especially in terms of clinically meaningful differences in the item-
response probabilities.  
After measurement invariance in the item-response probabilities was confirmed, 
we used the difference G2 test to examine the equivalence of latent class prevalences 
across men and women.  Two nested models were compared: 1) a model where women’s 
and men’s item-response probabilities were constrained to be equal but latent class 
prevalences were allowed to vary; and 2) a model in which the item-response 
probabilities and latent class prevalences for men and women were constrained to be 
equal.34  
The third phase evaluated correlates of the depression classes. Covariates were 
added to the four-class multiple-groups LCA in multinomial logistic models. Mild 
Depression served as the referent group to facilitate interpretation. Odds ratios of the 
difference in odds of membership in the Mild referent class compared to another class for 
individuals endorsing a particular covariate were derived from the multinomial logistic 
models. Unadjusted gender-specific odds ratios were estimated for each covariate and 
then the model was adjusted for all covariates. Sparseness was examined and ruled out.34  
Analyses were conducted using PROC LCA53,54 in SAS 9.3 and Mplus version 
7.2.55   
Results 
Women and men differed on several demographic and clinical characteristics 
(Table 2.1). Women were younger than men. Men were more likely than women to be 
white. Women had a more severe depression at baseline but had experienced fewer 
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depressive episodes, on average, than men. Of the individual QIDS-SR items, women 
were more likely to report sad mood, appetite changes, weight gain, impaired 
concentration, negative self-view, fatigue, and psychomotor retardation. Men were more 
likely than women to report suicidal ideation and psychomotor agitation. 
LCA Model 
A four-class base model was selected as optimal after examining fit statistics, 
latent class prevalences, and interpretability (Supplementary Table 2.1). Although the 
traditional fit statistics of AIC and BIC suggested the five-class model, the four-class 
model was ultimately selected since the additional fifth class was not readily 
distinguished from the others and had a very low prevalence. Sparseness did not appear 
to be an issue since no latent class prevalence estimate approached zero.  All four classes 
included participants likely to endorse sad mood but unlikely to endorse hypersomnia, 
decreased weight, suicidal ideation, or psychomotor disturbances (Supplementary Table 
2.2).  Two classes had high probabilities of endorsing most symptoms and thus seemed to 
represent more severe depression than the other classes. The Severe Depression with 
Insomnia class (31% of participants) had the highest probabilities of reporting sleep-onset 
insomnia, mid-nocturnal insomnia, and early morning insomnia. The Severe Depression 
with Increased Appetite (~16%) included those with a high probability of having 
increased appetite. The Moderate Depression class (23%) had many of the same 
symptoms as the severe classes but lower probabilities of endorsing these symptoms. The 
Mild Depression class (30%) was the least likely of all classes to have sad mood; 
members were unlikely to have early morning insomnia, hypersomnia, impaired 
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concentration, negative self-view, lack of general interest, fatigue, appetite or weight 
changes, and psychomotor disturbances.   
Gender Differences in Class Membership 
When gender was added as a grouping variable, a four-class solution was optimal 
for both genders (Supplementary Table 2.1). The difference G2 tests indicated that 
measurement invariance did not hold and the model with all parameters freed to vary by 
gender fit best.  However, because only the class prevalences and not the item-response 
probabilities varied by gender, the data were best described with the item-response 
probabilities constrained to be equal by gender (Table 2.2).  According to tests of 
equivalence of latent class prevalences, the proportions of women and men in each class 
differed for the Severe with Increased Appetite (p < 0.01), Severe with Insomnia (p = 
0.02) and Mild (p < 0.01) classes but not the Moderate class (p = 0.20). The Mild class 
was the most prevalent for men (37%) but the Severe with Insomnia class was most 
prevalent for women (31%). Almost twice as many women (22%) as men (13%) were in 
the Severe with Increased Appetite class.  
Demographic and Clinical Correlates of Class Membership  
Several demographic and clinical factors were correlates of class membership 
(Table 2.3). The Mild class served as the reference group in all models. Men in the 
Moderate class were less likely than those in the Mild class to be 45 years or older (aOR: 
0.41; 95% CI: 0.24-0.72) and to have comorbid PTSD (aOR: 0.28; 95% CI: 0.09-0.88) 
but more likely to have comorbid social phobia (aOR: 2.05; 95% CI: 1.12-3.76).  Those 
in the Severe with Increased Appetite class were more likely to have comorbid bulimia 
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(aOR: 12.29; 95% CI: 5.28-28.6) and social phobia (aOR: 3.22; 95% CI: 1.71-6.06) 
compared to men in the Mild class. Men in the Severe with Insomnia class were less 
likely to be 45 years or older (aOR: 0.65; 95% CI: 0.43-0.99) and more likely to have 
comorbid GAD (aOR: 2.07; 95% CI: 1.24-3.46), PTSD (aOR: 2.00; 95% CI: 1.24-3.24), 
and any other psychiatric comorbidity (aOR: 1.75; 95% CI: 1.14-2.68). 
Women in the Moderate class were less likely to be 45 years or older (aOR: 0.23; 
95% CI: 0.12-0.43) and to have any other psychiatric comorbidity (aOR: 0.40; 95% CI: 
0.21-0.74). Women in the Moderate class had greater odds of being white (aOR: 2.35; 
95% CI: 1.27-4.34) and of having comorbid social phobia (aOR: 3.12; 95% CI: 1.82-
5.36). Women in the Severe with Increased Appetite class were more likely than those in 
the Mild class to have comorbid GAD (aOR: 1.74; 95% CI: 1.06-2.85), bulimia (aOR: 
5.21; 95% CI: 3.16-8.59), and social phobia (aOR: 3.68; 95% CI: 2.36-5.75).  Those in 
the Severe with Insomnia class had lower odds of being white compared to women in the 
Mild class (aOR: 0.64; 95% CI: 0.44-0.93). Those in the Severe with Insomnia class had 
greater odds of having comorbid GAD (aOR: 2.91; 95% CI: 1.91-4.41), PTSD (aOR: 
2.30; 95% CI: 1.51-3.51), social phobia (aOR: 2.41; 95% CI: 1.60-3.63), and any other 
psychiatric comorbidity (aOR: 1.69; 95% CI: 1.19-2.41).  
Discussion 
This study sought to improve the understanding of depression subtypes based on 
clinically meaningful symptom patternsby utilizing the person-centered analytic approach 
of LCA. Four classes of depression were identified: Mild, Moderate, Severe with 
Increased Appetite, and Severe with Insomnia. Men and women experienced the same 
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patterns of depression symptoms but the proportions of men and women likely to be in 
the Mild, Severe with Increased Appetite, and Severe with Insomnia classes differed. 
Age, race, and psychiatric comorbidities were correlates of depression class membership. 
While STAR*D participants were required to have at least “moderate” depression 
as determined by an HRSD score  14,33,56 the Mild class had a relatively high probability 
of endorsing sad mood but low probabilities of endorsing all other DSM-IV depression 
symptom criteria. This class was the most common for men. The Moderate class was 
distinguished by probabilities of experiencing sad mood, impaired concentration, lack of 
general interest, and low energy that were higher than in the Mild class but lower than in 
the two Severe classes. Both Severe classes had very high probabilities of endorsing most 
of the depression criteria.  
The Severe with Insomnia class was the most prevalent class for women but the 
second most prevalent for men. The salience of insomnia symptoms in distinguishing this 
class is in line with how sleep disturbances are commonly both precursors57,58 and 
symptoms of depression.59 The difference in the latent class prevalences for women and 
men is consistent with women having a higher risk of insomnia than men.60 Consistent 
with previous reports linking sleep problems and anxiety,61,62 both men and women with 
anxiety disorders were more likely to be in this class than in the Mild class. Men and 
women 45 years or older were less likely to belong to the Severe with Insomnia class 
than to the Mild class, although for women this finding was attenuated after adjustment 
of other factors. This finding is contrary to reports that older age is associated with 
decreased sleep quality63 but differences between this sample and those of previous 
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studies, especially related to comorbid psychiatric conditions, could explain this 
contradiction. Addressing the insomnia symptoms for people in this class could be 
beneficial in reducing overall depression64 because insomnia is associated with 
depression recurrence57,65 and lack of antidepressant treatment response.66  
The gender difference in the Severe with Increased Appetite class prevalence was 
striking, with almost twice as many women in this class. Participants in this class also 
had substantially increased odds of having comorbid bulimia. The presence of this class 
supports findings that depression is bi-directionally associated with obesity,67,68 insulin 
resistance,69,70and diabetes.71,72  The lack of concurrently increased weight in this class 
might be due to the limited timeframe addressed by the QIDS-SR16 or comorbid bulimia 
and related dieting and compensating for overeating. Numerous pathophysiological 
mechanisms for the relationship between depression and appetite disturbances have been 
proposed, including hypothalamic-pituitary-adrenal (HPA) axis dysregulation,73 appetite-
stimulating effects of psychotropic medication,74 behaviors such as increased 
inflammation.75 The complex involvement of HPA axis dysregulation, cortisol, and 
brain-derived neurotrophic factor in bulimia76 and depression reinforces these areas as 
potential targets for treatment development.  
Depression subtypes of varying symptom patterns and those existing along a 
severity gradient have been proposed.22,77–79  The classes we identified share some 
similarities but do not correspond completely with traditional subtypes, including the 
melancholic, anxious and atypical DSM specifiers.59  For example, hypersomnia was not 
likely to be endorsed by any class despite being a hallmark feature of atypical depression. 
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Direct comparisons between classes from this analysis and those described in the DSM 
are not feasible because the QIDS-SR16 does not assess several DSM specifier criteria, 
such as diurnal variation. Moreover, the value of these specifiers remains to be 
determined, given persistent controversies over their validity.80 Numerous factors, 
including using the QIDS-SR16 for indicators and STAR*D’s clinical trial setting, must 
be considered when comparing our findings to others. 
  Our results should be interpreted with caution. STAR*D data were not originally 
designed to examine depression subgroups. STAR*D participants had depression, were 
seeking care, and enrolled in a clinical trial. This might lead to confounding by treatment-
seeking status, sampling bias due to the least severely depressed patients not being 
eligible to participate, and limited generalizability. STAR*D had broader eligibility 
criteria than most trials and this sample is more likely than other trials to be 
representative of patients seen in real-world settings.  
  The measurement of indicators and correlates of class membership might have 
introduced concerns. This analysis focused on baseline symptoms; how treatment-
emergent symptoms might alter the subgroups over time was beyond the scope of this 
work. The indicators were established by self-report on the QIDS-SR16, which might 
introduce response bias and lead to incorrect estimates of symptoms. Despite this, the 
QIDS-SR16 measures DSM depression criteria, is widely used in research and clinical 
care, and has been shown to be strongly correlated with clinician ratings and sensitive to 
changes in symptoms.81,82 Furthermore, LCA estimates and adjusts for measurement 
error.34   
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 This analysis is notable in several ways. It is one of the largest to use LCA, which 
is enhanced by sample sizes > 500,83 to examine depression subgroups. The models 
included several high quality indicators with item-response probabilities close to 0 or 184 
and clinically relevant correlates of depression class membership. Previous work has 
relied on regression models not well-suited to detecting subgroups. Such approaches to 
subgroup analysis can be limited by the vulnerability of multiple comparisons to Type I 
error rates and statistical power varying across the subgroups due to unbalanced sample 
sizes.35 These issues limit the possibility of examining higher-order interactions among 
subgroups.35  
 Our study suggests that sleep disturbances, appetite changes, and psychiatric 
comorbidities may differentiate subgroups of people with major depression. These latent 
classes differed by gender in the proportion of men and women belonging to each class. 
Our study demonstrates the potential of using a person-centered approach to detect 
subgroups based on not easily observable but clinically important symptom patterns. We 
demonstrated that LCA can be used to examine heterogeneity and identify subgroups for 
which treatment strategies can be tailored, a goal of precision medicine32 and the National 
Institute of Mental Health’s Research Domain Criteria initiative.85 
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Table 2.1: Baseline demographic and clinical characteristics of participants by gender 
Characteristic at study entry 
Women 
(n =1,763) 
Men 
(n = 1,009) p-value 
Mean age (SD)  40.0 (13.0) 43.0 (12.6) <0.001 
Race, n (%)    
White 1,313 (74.5) 802 (79.5) 0.012 
Black or African American 325 (18.4) 149 (14.8) 
Other 125 (7.1) 58 (5.8) 
Hispanic, n (%) 279 (15.8) 85 (8.4) <0.001 
Mean age at onset (SD) 24.3 (14.2) 23.7 (14.3) <0.001 
Mean duration (SD) 15.7 (13.0) 16.4 (13.4) 0.200 
Mean number of episodes (SD) 4.6 (7.5) 7.1 (11.4) <0.001 
Mean current depression severity (QIDS-SR16) (SD) 16.5 (16.5) 15.6 (3.9) <0.001 
Psychiatric comorbidities, n (%)    
GAD 467 (26.5) 188 (18.6) <0.001 
PTSD 371 (21.0) 203 (20.1) 0.563 
Bulimia 294 (16.7) 68 (6.7) <0.001 
Social phobia 581 (33.0) 288 (28.5) 0.016 
Any othera 705 (40.0) 463 (45.9) 0.003 
QIDS-SR16 items, n (%)    
Sleep onset insomnia 1,193 (67.7) 673 (66.7) 0.601 
Mid-nocturnal insomnia 1,298 (73.6) 722 (71.6) 0.239 
Early morning insomnia 874 (49.6) 493 (48.9) 0.696 
Hypersomnia 239 (13.6) 119 (11.8) 0.183 
Sad mood 1,528 (86.7) 812 (80.5) <0.001 
Decreased appetite 444 (25.2) 210 (20.8) 0.009 
Increased appetite 328 (18.6) 120 (11.9) <0.001 
Decreased weight 242 (13.7) 136 (13.5) 0.855 
Increased weight 245 (13.9) 89 (8.8) <0.001 
Impaired concentration 1,121 (63.6) 595 (59.0) 0.018 
Negative view of self 976 (55.4) 503 (49.9) 0.006 
Suicidal ideation 219 (12.4) 166 (16.5) 0.003 
Lack of general interest 1,049 (59.5) 593 (58.8) 0.729 
Fatigue 1,327 (75.3) 659 (65.4) <0.001 
Psychomotor slowing 637 (36.2) 310 (30.8) 0.004 
Psychomotor agitation 548 (31.1) 351(34.8) 0.043 
aAny other psychiatric comorbidity includes obsessive compulsive disorder, panic disorder, psychosis, 
agoraphobia, alcohol abuse/dependence, drug abuse/dependence, somatization, and/or hypochondriasis. 
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Table 2.2: Latent class prevalences and item-response probabilities of endorsing 
depression symptoms from a four-class LCA model of baseline QIDS-SR16 items by 
gender 
 
 Mild Moderate Severe with 
Increased 
Appetite 
Severe with 
Insomnia 
Latent Class Prevalence 
Men 37% 24% 13% 26% 
Women 27% 21% 22% 31% 
Item-Response Probabilities of QIDS-SR16 Indicators
1
 
Sleep onset insomnia 0.60 0.51 0.64 0.89 
Mid-nocturnal insomnia 0.73 0.58 0.70 0.86 
Early morning insomnia 0.45 0.23 0.51 0.72 
Hypersomnia 0.07 0.22 0.19 0.08 
Sad mood 0.63 0.88 0.95 0.97 
Decreased appetite 0.09 0.17 0.00 0.59 
Increased appetite 0.08 0.00 0.74 0.00 
Decreased weight 0.09 0.04 0.01 0.34 
Increased weight 0.07 0.03 0.42 0.03 
Impaired concentration 0.25 0.73 0.79 0.82 
Negative view of self 0.28 0.56 0.69 0.69 
Suicidal ideation 0.07 0.12 0.15 0.22 
Lack of general interest 0.27 0.69 0.74 0.77 
Fatigue 0.38 0.85 0.87 0.85 
Psychomotor retardation 0.12 0.32 0.46 0.32 
Psychomotor agitation 0.23 0.22 0.31 0.22 
1The item-response probabilities for each class were constrained to be equal across gender. 
 

34 
 
 
Supplementary Table 2.1: Fit information for LCA models of baseline depression 
symptoms without covariates 
# of 
Classes df AIC BIC CAIC 
Adjusted 
BIC Entropy  G
2
 
% of 
seeds 
associated 
with best 
fitted 
model 
Base Model Without Covariates 
2 65502 7720.58 7916.18 7949.18 7811.33 0.60 7654.58 100 
3 65485 6918.83 7215.20 7265.20 7056.33 0.64 6818.83 100 
4 65468 6767.30 7134.43 7201.43 6921.55 0.62 6603.30 100 
5 66045 6622.11 7120.00 7204.00 6853.11 0.70 6454.11 15 
6 65434 6548.30 7146.96 7247.96 6826.05 0.65 6346.30 20 
7 65417 6494.96 7194.39 7312.39 6819.46 0.66 6258.96 5 
Gender as Grouping Variable: Without Measurement Invariance 
2 131005 9828.18 10219.38 10285.38 10009.68 0.60 9696.18 100 
3 100971 9039.94 9632.68 9732.68 9314.94 0.64 8839.94 100 
4 130937 8881.03 9675.29 9809.29 9249.53 0.63 8613.03 45 
5 130903 8768.33 9764.12 9932.12 9230.32 0.69 8432.33 5 
6 130869 8701.20 9898.52 10100.52 9256.70 0.68 8297.20 5 
7 130835 8656.84 10055.69 10291.69 9305.84 0.65 8184.84 5 
Gender as Grouping Variable: With Measurement Invariance 
2 131037 9863.89 10065.42 10099.42 9957.39 0.60 9795.89 100 
3 131019 9055.45 9363.67 9415.67 9198.45 0.64 8951.45 100 
4 131001 8868.27 9283.18 9353.18 9283.18 0.64 8728.27 30 
5 130983 8756.21 8756.21 9277.82 8998.21 0.70 8580.21 10 
6 130965 8679.39 9307.69 9413.69 8970.89 0.66 8467.39 30 
7 130947 8624.83 9359.82 9483.82 8965.83 0.66 8376.83 5 
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Supplementary Table 2.2: Latent class prevalences and item-response probabilities of 
endorsing depression symptoms from a four-class model of baseline QIDS-SR16 items  
Symptoms 
Mild Moderate Severe with 
Increased 
Appetite 
Severe with 
Insomnia 
Latent Class Prevalence  
 30% 23% 16% 31% 
Item-Response Probabilities of QIDS-SR16 Indicators 
Sleep onset insomnia 0.61 0.48 0.68 0.88 
Mid-nocturnal insomnia 0.74 0.56 0.73 0.85 
Early morning insomnia 0.46 0.21 0.57 0.71 
Hypersomnia 0.07 0.24 0.17 0.09 
Sad mood 0.63 0.89 0.95 0.98 
Decreased appetite 0.09 0.13 0.00 0.58 
Increased appetite 0.08 0.09 0.74 0.00 
Decreased weight 0.09 0.04 0.09 0.33 
Increased weight 0.07 0.04 0.48 0.05 
Impaired concentration 0.24 0.74 0.80 0.82 
Negative view of self 0.28 0.55 0.71 0.68 
Suicidal ideation 0.07 0.11 0.16 0.21 
Lack of general interest 0.27 0.68 0.76 0.77 
Fatigue 0.39 0.84 0.88 0.86 
Psychomotor retardation 0.12 0.31 0.48 0.51 
Psychomotor agitation 0.23 0.20 0.33 0.51 
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CHAPTER III 
 GENDER DIFFERENCES IN CHANGES IN DEPRESSION SUBGROUPS IN 
STAR*D - A LATENT TRANSITION ANALYSIS 
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Abstract 
Objective: To characterize gender differences in latent statuses of major depression and 
changes in these statuses among adults receiving citalopram in the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) trial. 
Method: Latent transition analysis was applied to data from 387 men and 755 women 
who completed baseline and week 12 study visits in level 1 of STAR*D. Items from the 
self-report version of the Quick Inventory of Depressive Symptomatology were used as 
indicators of latent depression status.  
Results: Four statuses were identified for each gender at baseline and week 12. Baseline 
statuses for men were MildMen (10%), ModerateMen (53%), Severe with Psychomotor 
Slowing (20%), and Severe with Psychomotor Agitation (17%). For men at week 12, the 
statuses were Symptom ResolutionMen (41%), MildMen (36%), ModerateMen (18%), and 
Severe with Psychomotor Slowing (5%). Baseline statuses for women were MildWomen 
(21%), ModerateWomen (30%), Severe with Increased Appetite (16%), and Severe with 
Decreased Appetite (34%). For women, week 12 statuses were Symptom ResolutionWomen 
(65%), MildWomen (23%), ModerateWomen (9%), and Severe with Psychomotor 
Disturbances (3%). Men in the Mild status at baseline were most likely to transition to 
Symptom Resolution (probability = 69%). Men in the Severe with Psychomotor 
Agitation status did not transition to Symptom Resolution. Women in the Moderate status 
had the greatest chance of moving to Symptom Resolution (87%). Women in the Severe 
with Decreased Appetite status had the lowest chance of transitioning to Symptom 
Resolution (46%). 
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Conclusions: Depression severity and psychomotor disturbances distinguished 
depression statuses for men whereas severity, appetite, and insomnia distinguished 
statuses for women. After treatment, depression severity characterized statuses for men 
but psychomotor and sleep disturbances characterized women. This work highlights the 
need to consider symptoms and not focus solely on summary rating scores when treating 
depression. 
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Introduction 
 Heterogeneity in major depression is well established, with more than 1,400 
combinations of DSM criteria symptoms possible12 and considerable differences in 
illness course, prominent symptoms, and treatment response.13 Depression subtypes 
based on symptom patterns have been proposed but the extent to which these subtypes or 
even individual symptoms change over time is not clear.  It has been seen that individual 
symptoms29,30 and subtypes31 can change throughout depressive episodes but few studies 
have been conducted and treatment is rarely considered. Research about the longitudinal 
stability of subtypes, including transitions between subtypes in response to treatment, 
could inform efforts to address depression symptom heterogeneity in personalizing 
treatment strategies, a goal of precision medicine and the National Institute of Mental 
Health’s Research Domain Criteria (RDoC) initiative.32 
 Latent transition analysis (LTA) is one potential method for efficiently 
determining depression subgroups by incorporating numerous patterns of depression 
symptoms and examining how these subgroups change over time. LTA is a longitudinal 
extension of latent class analysis, a finite mixture modeling method that posits that there 
are mutually exclusive and exhaustive “statuses,” or groups, of people that can be 
distinguished by values of an unobserved variable.34 This latent variable is comprised of 
observed indicator variables of characteristics such as depression symptoms. LTA can be 
used to model changes in the qualitative nature of these statuses, in the prevalence of 
each status at each time, and in the individuals’ membership in these statuses over time. 
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To our knowledge, only two other studies to date have used LTA to look at the stability 
of types of depression over time and treatment was unknown in both studies.86,87  
 This study sought to use LTA to characterize statuses of major depression for men 
and women and to examine changes in statuses after receiving citalopram treatment in 
level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. 
The objectives were to: 1) characterize patterns of depression symptoms at the beginning 
of a treatment trial; 2) examine changes in these patterns, including changes in the 
descriptive nature of each status and how participants move between statuses, over 12 
weeks of treatment; and 3) examine gender differences in these statuses. 
Methods 
Study Participants 
 The publicly available, de-identified dataset from level 1 of STAR*D was used. 
STAR*D was a pragmatic clinical trial originally designed to assess the effectiveness of a 
variety of pharmacological and psychosocial treatments for moderate-to-severe non-
psychotic major depression.42 Between July 2001 and April 2004, 4,041 participants were 
enrolled from 18 primary care and 23 outpatient psychiatric sites. In level 1, participants 
received citalopram for up to 14 weeks. Study visits were conducted at 2, 4, 6, 9, and 12 
weeks with an optional visit at week 14. Of the evaluable sample of participants who 
scored ≥ 14 on the baseline 17-item Hamilton Rating Scale of Depression (HRSD) and 
completed ≥ one post-baseline visit,45 almost 30% achieved remission (HRSD ≤ 7 or last 
observed 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16) score ≤ 
5) and 47% experienced response (≥ 50% reduction in baseline QIDS-SR16 score).
33 
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Additional details about STAR*D have been described elsewhere.33,42  
This analysis sought to quantify transitions in depression statuses over a 12-week 
period.  As such, participants must have completed baseline and week 12 study visits. 
While LTA can theoretically accommodate some missing data for the indicator variables 
used to define the statuses at the different time points, we used a complete cases analysis 
because we were unable to achieve model convergence when all participants, regardless 
of whether they completed the week 12 assessment, were included. Additionally, 56 
participants were excluded because they had missing data on key variables of interest 
(e.g. QIDS-SR16, etc.). The remaining 1,142 participants comprised the study sample. 
STAR*D participants provided written informed consent after receiving a 
complete description of the study at enrollment. The protocol was originally approved 
and monitored by the institutional review boards at the trial’s national coordinating 
center, the data coordinating center, clinical sites, and the Data, Safety, and Monitoring 
Board of the National Institute of Mental Health. The Institutional Review Board at the 
University of Massachusetts Medical School determined that this secondary analysis was 
not human subject research as defined by Department of Health and Human Services and 
Food and Drug Administration regulations. 
Measures 
Indicators of Latent Status Membership 
The individual QIDS-SR16 items collected at baseline and week 12 were used as 
indicators of latent depression status. The QIDS-SR16 measures depression severity and 
contains 16 items corresponding to the nine DSM-IV symptom criterion domains for 
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major depression.46 All items except weight change reflect the past seven days whereas 
the weight change items reflect the last 14 days. The individual item scores range from 0-
3, with any item score ≥ 2 indicating that the symptom meets the DSM-IV threshold for 
major depression.44 Thus, for this analysis, all items were dichotomized with individual 
item scores ≤ 1 denoting the absence of a DSM-IV criterion symptom. Scores ≥ 2 signify 
the presence of a criterion symptom. The QIDS-SR16  instructions stipulate that only one 
item on appetite increase or decrease and weight increase or decrease should be 
completed. We included four separate indicator variables to better capture the direction 
changes in appetite and weight. 
Gender Differences in Latent Statuses 
Gender differences have been documented in many aspects of depression, 
including rates, severity, course, risk factors, and symptoms. Women experience 
depression more often and more severely than men.17–20 Women also seem to be more 
likely to experience somatic, atypical, and anxiety symptoms21–23 and to have more 
transitions between subtypes.87 Because of these established differences, we hypothesized 
that men and women would not experience depression and treatment response similarly 
and sought to evaluate if depression statuses at each time were qualitatively the same for 
men and women. 
Analysis 
 The statistical analysis was conducted in three phases: 1) describing the overall 
sample and comparing characteristics of those included and excluded from the analysis; 
2) developing the basic latent status model for transitions between baseline and week 12 
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of the trial; and 3) determining if the depression statuses differed for men and women.  
First, we compared demographic and clinical characteristics of those meeting our 
eligibility criteria to those excluded from the analysis. Because trivial differences were 
likely to achieve statistical significance owing to the large sample size, we considered 5% 
absolute differences in the prevalence estimates between those included and excluded to 
be noteworthy. For the second phase of the analysis, we fit multiple basic LTA models, 
varying the number of statuses. Selecting the optimal number of latent statuses was 
informed by fit statistics such as Akaike Information Criterion (AIC) and Bayesian 
Information Criterion (BIC) and the interpretability of the statuses. The relative fit of the 
models was emphasized over traditional hypothesis testing because of issues arising from 
LTA models having very large degrees of freedom and extreme sparseness.34 After the 
optimal number of latent statuses was selected for the basic LTA model, the assumption 
of measurement invariance of the qualitative nature of the statuses was tested across time. 
This was done using the difference G2 test,34 AIC and BIC to compare two nested 
models: 1) a model in which the item-response probabilities were allowed to vary 
between baseline and week 12; and 2) a model in which the item-response probabilities 
were constrained for both time points. The measurement invariance assumption was not 
supported and the analysis proceeded under the assumption that there were differences in 
the depression statuses at baseline and week 12. 
 In the third phase of analysis, LTA models with gender as a grouping variable 
were fit. The optimal number of latent statuses was selected using a similar strategy as 
described in phase two of the analysis. Measurement invariance between men and women 
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and across time was then tested using the G2 difference test to compare several nested 
models: 1) a model in which the item-response probabilities were free to vary between 
men and women and across times; 2) a model in which the item-response probabilities 
were constrained to be equal across times but were allowed to vary by gender; 3) a model 
in which item-response probabilities were constrained to be equal in men and women but 
were allowed to vary by time; and 4) a model in which item-response probabilities were 
constrained to be equal across gender and times. Models 2-4 were compared to model 1 
using separate tests. Measurement invariance could not be established across genders and 
times and thus separate LTA models for men and women were ultimately investigated. 
The analysis described above for the basic LTA of all participants was conducted 
separately for each gender.34 Analyses were conducted using PROC LTA53,88 in SAS 9.3 
(SAS Institute, Inc., Cary, NC). 
Results 
Overall Sample 
 Participants who completed a baseline and week 12 study visit were mostly 
women, were in their early- to mid-40’s, white, and had moderate to severe depression 
(Table 3.1). Men who were included in this analysis were similar to those who were 
excluded. When compared to included women, the women who were excluded were two 
years younger on average. The excluded women were also more likely to be black or 
African American, and more likely to have comorbid anxiety disorders such as 
generalized anxiety disorder, PTSD, and social phobia at baseline when differences in 
frequency  5% were considered.   
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 The fit statistics for LTA models in the first phase of analysis supported a four-
status model (Supplementary Table 3.1). The G2 difference test of the measurement 
invariance hypothesis of the item-response probabilities across time was significant (𝐺2
2-
𝐺1
2 =252.67, df = 64, p <0.0001) and thus it could not be assumed that the latent statuses 
were qualitatively the same at baseline and week 12. The statuses at baseline were 
primarily distinguished by depression severity and were labeled Mild Depression, 
Moderate Depression, Severe Depression with Insomnia, and Severe Depression with 
Increased Appetite (Supplementary Table 3.2). Thirty percent of participants were likely 
to be in the Severe with Insomnia status, 28% in the Mild status, 25% in the Moderate 
status, and 18% in the Severe with Increased Appetite status. Members of all statuses 
were likely to endorse having mid-nocturnal insomnia and sad mood. All participants 
except for members of the Mild status were likely to report having impaired 
concentration, negative self-view, lack of general interest, and fatigue. The statuses at 
week 12 were still mainly differentiated by severity but with the statuses identified as 
Symptom Resolution, Mild Depression with Insomnia, Moderate Depression, and Severe 
Depression with Insomnia. The symptom pattern of the Severe with Insomnia status at 
week 12 was similar to that of baseline except for having higher probabilities of the 
insomnias, impaired concentration, and negative self-view. The majority of participants 
at week 12 were likely to belong to the Symptom Resolution status (61%) and the fewest 
were in the Severe with Insomnia status (6%).  
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Men 
 On average, the men included in this analysis were likely to be middle-aged, 
white, and have a QIDS-SR16 score indicative of moderate depression at baseline (Table 
3.1). Anxiety disorders were the most common psychiatric comorbidity, with social 
phobia being the most prevalent. The majority of men were experiencing sleep-onset 
insomnia, mid-nocturnal insomnia, sad mood, impaired concentration, lack of interest, 
and fatigue at baseline but mid-nocturnal insomnia was the only depression symptom 
experienced by a majority by week 12 (Table 3.2).  
A four-status LTA model fit the data best at both baseline and week 12. At 
baseline, the statuses were Mild DepressionMen, Moderate DepressionMen, Severe 
Depression with Psychomotor Slowing, and Severe Depression with Psychomotor 
Agitation (Table 3.3). At week 12, the MildMen, ModerateMen, and Severe with 
Psychomotor Slowing statuses were still present but a Symptom ResolutionMen status also 
emerged. The G2 difference test suggested that measurement invariance of the overall 
item-response probabilities across time could not be assumed, meaning that the statuses 
were qualitatively different at each time (𝐺2
2-𝐺1
2 = 117.53, df = 64, p < 0.0001) 
(Supplementary Table 3.3). After thoroughly considering the interpretation of each 
individual status at each time, however, measurement invariance was assumed for the 
MildMen, ModerateMen, and Severe with Psychomotor Slowing statuses between baseline 
and week 12. At baseline, the most men were likely to belong to the ModerateMen status 
(53% of men) (Figure 3.1). The least prevalent status was MildMen (10% of men). 
Members of the MildMen status at baseline were the most likely to transition to the 
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Symptom ResolutionMen status, with a 69% chance of making this transition. None of 
those in the Severe with Psychomotor Agitation status transitioned to the Symptom 
ResolutionMen status at week 12. Men in the Severe with Psychomotor Slowing statuses 
were least likely to transition to a less severe status, with a 23% of remaining in the 
Severe Psychomotor Slowing status at week 12. Conversely, men in the MildMen status at 
baseline were the least likely to move into a more severe status, with none transitioning to 
the ModerateMen or Severe with Psychomotor Slowing status. Overall, 41% of men were 
likely to be in the Symptom ResolutionMen status at week 12.  
Women 
At baseline, the women included in this analysis were mostly in their early 40s, 
white, and severely depressed (Table 3.1). Anxiety disorders were the most frequently 
occurring psychiatric comorbidities at baseline. Social phobia was the most common 
comorbidity. Women who were excluded were more likely than those included to be 
black or African-American, have GAD, have PTSD, or have social phobia. Of the 
criterion depression symptoms, the majority of included women were experiencing sleep-
onset insomnia, mid-nocturnal insomnia, sad mood, impaired concentration, negative 
self-view, lack of interest, and fatigue at baseline (Table 3.2). Mid-nocturnal insomnia 
was the only symptom still experienced by most women by week 12.   
 An LTA model with four statuses most appropriately described the baseline and 
week 12 data. At baseline, the four statuses were MildWomen, ModerateWomen, Severe with 
Increased Appetite, and Severe with Decreased Appetite (Table 3.4). The statuses at 
week 12 were Symptom ResolutionWomen, MildWomen, ModerateWomen, and Severe with 
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Psychomotor Disturbances. The qualitative descriptions of the overall statuses appeared 
to change over time (𝐺2
2-𝐺1
2 = 168.95, df = 64, p < 0.0001) (Supplementary Table 3.3) but 
the item-response probabilities for the Mild statuses at each time were similar. As such, 
measurement invariance was imposed on these statuses. The same was true for the 
Moderate statuses at baseline and week 12. 
 The baseline Severe with Decreased Appetite status was the most prevalent 
(34%), followed by the Moderate status (30%) (Figure 3.2). The Severe with Increased 
Appetite status was the least prevalent (16%). The Symptom ResolutionWomen status was 
the most prevalent (65%) at week 12 while the Severe with Psychomotor Disturbances 
was the least common (3%). Women who were most likely to belong to the Moderate 
status at baseline had the highest chance of transitioning to the Symptom ResolutionWomen 
status at week 12 (87%). Women in the Severe with Increased Appetite and Severe with 
Decreased Appetite statuses were also more likely to transition to the Symptom 
Resolution status than to any other status (transition probability = 48% and 46%, 
respectively). The probability that women in the MildWomen and ModerateWomen statuses at 
baseline transitioned into the Severe with Psychomotor Disturbances group at week 12 
was zero. While women in the MildWomen status at baseline had a 26% chance of 
remaining in that status at week 12, women in the ModerateWomen status at baseline had a 
13% of staying in that status at week 12. Women in the Severe with Increased Appetite 
status and those in the Severe with Decreased Appetite status had a 3% and 8% chance of 
moving to the Severe with Psychomotor Disturbances status, respectively. 
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Discussion 
 The primary objective of this study was to use LTA to explore changes in 
depression statuses for men and women through 12 weeks of citalopram treatment. Four 
different statuses were identified at each time point for each gender. Depression severity 
and psychomotor disturbances were common distinguishing features of the statuses for 
both men and women. The majority of men and of women were likely to transition into 
statuses that were characterized by fewer dominant symptoms, an improvement obscured 
when defining treatment success by looking only at those meeting criteria for complete 
symptom remission.   
 In men, we found that severe depression was further differentiated by 
psychomotor symptoms. This finding agrees with previous work noting psychomotor 
disturbances in depression.89 Despite such focus on these psychomotor symptoms and the 
assumption that they are core features of melancholic depression, it remains unclear if 
both symptoms are core features of melancholia or are shared across depression 
subtypes.90 Agitation is also associated with mood-switching in unipolar depression91 and 
with comorbid substance dependence,92 highlighting the need to determine how to 
improve treatment to resolve specific symptoms. After 12 weeks of treatment, 
psychomotor disturbances no longer differentiated depression subgroups in men but we 
found that men who started in the Severe with Psychomotor Slowing group had the 
lowest chances of improving. This is consistent with previous work demonstrating that 
psychomotor retardation is related to greater depression severity93 and poor response to 
citalopram.94 Psychomotor retardation appears to involve the hypothalamic-pituitary-
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adrenal (HPA) axis, basal ganglia, and prefrontal cortex95 and is associated with 
differential treatment response, with improvements seen in depression with psychomotor 
slowing when treated with fluoxetine and sertraline but not with citalopram.96 This 
suggests potential areas for targeted treatment. 
 In women, appetite changes were influential in distinguishing statuses at baseline. 
This is similar to our previous findings that increased appetite was associated with 
separate severe depression subgroups in a latent class analysis of STAR*D participants at 
baseline (Chapter II). That both increased and decreased appetite symptoms were 
prominent at baseline is in line with melancholic depression being associated with 
diminished appetite and atypical depression with hyperphagia. These behaviors have 
been proposed to result from distinct dysregulations of the stress response system, 
particularly related dysfunction in activation of corticotropin-releasing hormone (CRH).97 
It is encouraging, however, that the subgroups experiencing appetite changes were highly 
likely to transition to either the Symptom ResolutionWomen or MildWomen statuses. That 
insomnia was still experienced by almost a third of women at week 12 is consistent with 
previous research. Insomnia is known to play a large role in depression, especially for 
women,60 and is associated with depression recurrence57 and inadequate treatment 
response.98 Insomnia is also a side effect of many antidepressants. Considering residual 
symptoms such as insomnia may be necessary for improving depression treatment since 
residual symptoms increase risk of relapse44 and since doing so may elucidate important 
clues for how to target symptoms to produce overall depression remission and improved 
functioning.99 
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 While this analysis used data from the largest and longest depression treatment 
trial to examine latent depression statuses and changes in statuses membership over time, 
our results do have several limitations. This is a post-hoc analysis of data that was not 
originally collected for the purposes of performing such subgroup analyses. Furthermore, 
this complete case analysis included not only individuals who were seeking care in 
primary care or psychiatric outpatient settings and enrolled in a clinical trial but was 
limited to those who attended both the baseline and week 12 study visits. While there did 
not appear to be substantial differences in sociodemographic and clinical characteristics 
between those who were included and excluded from our analysis, biased estimates from 
the complete case analysis are still possible and generalizability of results might be 
limited.  STAR*D, however, had broader inclusion criteria than most clinical trials and 
this sample is more representative of people seeking outpatient depression treatment than 
are participants from other clinical trials.40 Overall, level 1 of STAR*D is a strong source 
of observational data where, unlike in other naturalistic studies, treatment is known. 
 Psychomotor disturbances and the other depression symptoms used as indicators 
of the latent depression status variable were drawn from the self-report QIDS and not 
confirmed through clinical observation. This could introduce response bias, produce 
inaccurate estimates of symptoms, and limit comparison to other studies of depression, 
particularly those using objective assessments of psychomotor disturbances. The timing 
of the assessment and the length of the trial must be considered when interpreting our 
findings. The QIDS-SR16 inquires about symptoms from the previous 1-2 weeks, which 
might not be adequate to capture all symptom changes, especially those related to longer 
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processes such as weight changes. Furthermore, although 12 weeks is not an uncommon 
length of time for a clinical trial, it might not be sufficient to identify all the transitions 
that might occur with antidepressant treatment.  
 Despite these considerations, this analysis is noteworthy in several ways. 
Although only complete cases were used, this sample is the largest in which LTA has 
been used to examine at the stability of depression subgroups during known 
antidepressant treatment. LTA models consolidate large arrays of contingency table data 
representing multidimensional constructs, such as depression, into meaningful subgroups. 
This efficiency is especially valuable when examining the heterogeneity that can arise 
from combinations of 16 depression symptoms at two time points. One study on the 
frequency of symptom patterns observed in STAR*D reported 1,030 unique symptom 
profiles at baseline, the majority of which were endorsed by five or fewer participants.100 
Because LTA also allows for measurement error, it does not penalize models when 
participants’ symptoms do not clearly suggest membership in one particular status.   
 Our results indicate that men and women experienced different patterns of 
depression symptoms during citalopram treatment in level 1 of STAR*D and that these 
patterns were not stable over time. While there has been continual interest in elucidating 
subgroups of depression, the stability of subgroups has received far less attention. Our 
study demonstrates the potential of using the person-centered approach of LTA to detect 
subgroups comprised of important symptom patterns and to examine changes in these 
subgroups during treatment. LTA can be used to examine heterogeneity and identify 
subgroups, work that can eventually inform the development of tailored treatments.  
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Table 3.1: Baseline demographic and clinical characteristics of men and women by study 
inclusion status 
 
 Men  Women  
Characteristic 
Included  
N = 387 
Excluded  
N = 657 p-value 
Included  
N = 755 
Excluded  
N = 1,077 p-value 
Age at study entry, mean 
(SD) 
44.6 (12.5) 42.3 (12.6) 0.004 41.4 (13.2) 39.4 (12.9) 0.001 
Race, n (%) 
White 303(78.3) 519 (79.0) 0.871 581 (77.0) 776 (72.1) 0.008 
Black or African 
American 
62 (16.0) 98 (14.9)  117 (15.5) 229 (21.3)  
Other 22 (5.7) 40 (6.1)  57 (7.6) 72 (6.7)  
Hispanic, n (%) 31 (8.0) 58 (8.8) 0.648 103 (13.6) 182 (16.9) 0.058 
Age at onset, mean (SD) 27.3 (14.7) 26.5 (14.2) 0.394 24.8 (14.6) 24.3 (14.1) 0.409 
Number of depressive 
episodes before baseline, 
mean (SD) 
7.9 (12.8) 6.5 (10.3) 0.088 4.5 (6.4) 4.7 (8.3) 0.645 
Depression severity (QIDS-
SR16) at baseline, mean 
(SD) 
15.3 (3.9) 15.8 (4.0) 0.059 16.1 (4.0) 16.8 (4.0) <0.001 
Psychiatric comorbidities, n (%) 
GAD 74 (19.3) 118 (18.3) 0.689 171 (22.9) 309 (29.2) 0.003 
PTSD 78 (20.4) 127 (19.8) 0.812 115 (15.5) 261 (24.8) <0.001 
Bulimia 26 (6.7) 44 (6.8) 0.973 122 (16.4) 178 (16.8) 0.822 
Social phobia 110 (28.8) 182 (28.2) 0.831 211 (28.5) 384 (36.3) <0.001 
OCD 44 (11.5) 83 (12.8) 0.518 62 (8.3) 125 (11.8) 0.017 
Panic disorder 42 (11.0) 75 (11.6) 0.753 89 (11.9) 164 (15.5) 0.033 
Psychosis 48 (12.5) 103 (15.9) 0.138 87 (11.7) 159 (15.0) 0.041 
Agoraphobia 35 (9.1) 79 (12.2) 0.129 75 (10.2) 144 (13.7) 0.026 
Alcohol 
abuse/dependence 
67 (17.5) 118 (18.2) 0.789 65 (8.7) 92 (8.7) 0.991 
Drug abuse/dependence 38 (9.9) 68 (10.5) 0.749 34 (4.6) 68 (6.4) 0.088 
Somatization disorder 3 (0.8) 7 (1.1) 0.636 19 (2.6) 40 (3.8) 0.143 
Hypochondriasis 6 (1.6) 29 (4.5) 0.012 31 (4.2) 60 (5.7) 0.148 
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Table 3.2: Frequency of QIDS-SR16 items at baseline and week 12 for men and women 
included in this analysis 
 
 
Men 
(n= 387) 
 Women 
(n= 755) 
 Baseline Week 12  Baseline Week 12 
QIDS-SR16 items N (%) N (%)  N (%) N (%) 
Sleep-onset insomnia 246 (63.6) 125 (32.3)  488 (64.6) 206 (27.3) 
Mid-nocturnal insomnia 271 (70.0) 237 (61.2)  541 (71.7) 428 (56.7) 
Early morning insomnia 180 (46.5) 95 (24.6)  365 (48.3) 148 (19.6) 
Hypersomnia 38 (9.8) 37 (9.6)  114 (15.1) 61 (8.1) 
Sad mood 312 (80.6) 93 (24.0)  641 (84.9) 137 (18.2) 
Decreased appetite 80 (20.7) 22 (5.7)  165 (21.9) 31 (4.1) 
Increased appetite 41 (10.6) 25 (6.5)  146 (19.3) 51 (6.8) 
Decreased weight 52 (13.4) 11 (2.8)  89 (11.8) 22 (2.9) 
Increased weight 27 (7.0) 18 (4.7)  92 (12.2) 34 (4.5) 
Impaired concentration 220 (56.9) 77 (19.9)  454 (60.1) 106 (14.0) 
Negative view of self 179 (46.3) 65 (16.8)  417 (55.2) 110 (14.6) 
Suicidal ideation 51 (13.2) 19 (4.9)  84 (11.1) 29 (3.8) 
Lack of interest 226 (58.4) 70 (18.1)  444 (58.8) 135 (17.9) 
Fatigue 244 (63.1) 69 (17.8)  563 (74.6) 158 (20.9) 
Psychomotor retardation 126 (32.6) 46 (11.9)  263 (34.8) 64 (8.5) 
Psychomotor agitation 130 (33.6) 59 (15.3)  221 (29.3) 82 (10.9) 
 
  
 
 
 
Table 3.3: Item-response probabilities from a four-status LTA of QIDS-SR16 indicators for men 
Men 
(n=387) 
 Baseline Latent Statuses  Week 12 Latent Statuses 
 
MildMen
1
 
 
ModerateMen
2
 
Severe with 
Psychomotor 
Slowing
3
 
Severe with 
Psychomotor 
Agitation  
Symptom 
ResolutionMen MildMen
1
 ModerateMen
2
 
Severe with 
Psychomotor 
Slowing
3
 QIDS-SR16 items 
Sleep onset 
insomnia 0.35 0.56 0.82 0.83  0.13 0.35 0.56 0.82 
Mid-nocturnal 
insomnia 0.71 0.69 0.83 0.76  0.39 0.71 0.69 0.83 
Early morning 
insomnia 0.35 0.34 0.66 0.86  0.00 0.35 0.34 0.66 
Hypersomnia 0.05 0.15 0.12 0.00  0.09 0.05 0.15 0.12 
Sad mood 0.11 0.84 0.89 0.89  0.06 0.11 0.84 0.89 
Decreased appetite 0.05 0.07 0.44 0.49  0.00 0.05 0.07 0.44 
Increased appetite 0.07 0.17 0.08 0.00  0.00 0.07 0.17 0.08 
Decreased weight 0.04 0.07 0.16 0.34  0.01 0.04 0.07 0.16 
Increased weight 0.05 0.10 0.06 0.00  0.03 0.05 0.10 0.06 
Impaired 
concentration 0.59 0.51 0.93 0.59  0.01 0.59 0.51 0.93 
Negative self-view 0.41 0.47 0.76 0.41  0.02 0.41 0.47 0.76 
Suicidal ideation 0.03 0.15 0.24 0.03  0.02 0.03 0.15 0.24 
Lack of general 
interest 0.72 0.51 0.81 0.72  0.00 0.72 0.51 0.81 
Fatigue 0.63 0.57 0.96 0.63  0.00 0.63 0.57 0.96 
Psychomotor 
retardation 0.27 0.21 0.86 0.27  0.00 0.27 0.21 0.86 
Psychomotor 
agitation 0.62 0.26 0.45 0.62  0.00 0.62 0.26 0.45 
1The the item-response probabilities for the MildMen statuses were constrained to be equal at baseline and week 12. 
2The item-response probabilities for the ModerateMen statuses were constrained to be equal at baseline and week 12.
 
3The item-response probabilities for the Severe with Pychomotor Slowing statuses were constrained to be equal at baseline and week 12. 
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Table 3.4: Item-response probabilities from four-status LTA of QIDS-SR16 indicators for women  
Women 
(n=775) 
 Baseline Latent Statuses  Week 12 Latent Statuses 
QIDS-SR16 items MildWomen
1
 ModerateWomen
2
 
Severe with 
Increased 
Appetite 
Severe with 
Decreased 
Appetite  
Symptom 
ResolutionWomen MildWomen
1
 
 
ModerateWomen
2
 
Severe with 
Psychomotor 
Disturbances 
Sleep onset 
insomnia 0.54 0.46 0.69 0.86  0.12 0.54 0.46 0.82 
Mid-nocturnal 
insomnia 0.77 0.56 0.73 0.82  0.48 0.77 0.56 0.87 
Early morning 
insomnia 0.47 0.24 0.58 0.66  0.06 0.47 0.24 0.74 
Hypersomnia 0.01 0.30 0.22 0.10  0.06 0.01 0.30 0.13 
Sad mood 0.44 0.79 0.99 0.97  0.03 0.44 0.79 1.00 
Decreased 
appetite 0.07 0.10 0.00 0.51  0.01 0.07 0.10 0.28 
Increased appetite 0.08 0.17 0.85 0.00  0.04 0.08 0.17 0.22 
Decreased weight 0.06 0.05 0.00 0.28  0.01 0.06 0.05 0.04 
Increased weight 0.07 0.04 0.55 0.03  0.03 0.07 0.04 0.20 
Impaired 
concentration 0.18 0.65 0.72 0.75  0.02 0.18 0.65 1.00 
Negative self-
view 0.22 0.52 0.71 070  0.03 0.22 0.52 0.87 
Suicidal ideation 0.09 0.05 0.16 0.16  0.00 0.09 0.05 0.26 
Lack of general 
interest 0.25 0.55 0.77 0.77  0.06 0.25 0.55 0.83 
Fatigue 0.33 0.79 0.89 0.87  0.06 0.33 0.79 0.95 
Psychomotor 
retardation 0.11 0.32 0.49 0.49  0.00 0.11 0.32 0.57 
Psychomotor 
agitation 0.21 0.21 0.27 0.46  0.02 0.21 0.21 0.53 
1The item-response probabilities for the MildWomen statuses were constrained to be equal at baseline and week 12. 
2The item-response probabilities for the ModerateWomen statuses were constrained to be equal at baseline and week 12.
 
56 


59 
 
 
Supplementary Table 3.1: Fit indices for basic LTA models of QIDS-SR16 at baseline and 
12 weeks 
 
# of Statuses df G
2
 AIC BIC 
No Measurement Invariance 
2 4294967228 15587.75 15721.75 16059.46 
3 4294967191 15039.40 15247.40 15771.62 
4 4294967152 14838.00 15124.00 15844.79 
5 4294967111 14645.86 15013.86 15941.32 
6 4294967068 14518.52 14972.52 16116.72 
7 4294967023 14392.01 14936.01 16307.03 
Measurement Invariance 
Rho parameters constrained to be equal across time 
2 4294967260 16044.22 16114.22 16290.64 
3 4294967239 15488.38 15600.38 15882.65 
4 4294967216 15081.96 15239.96 15638.16 
5 4294967191 14917.95 15125.95 15650.17 
6 4294967164 14789.00 15051.00 15711.31 
7 4294967135 14685.09 15005.09 15811.57 
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Supplementary Table 3.2: Latent status prevalences and item-response probabilities from four-status LTA of QIDS-SR16 
indicators without constraints on any parameters  
 Baseline Latent Statuses  Week 12 Latent Statuses 
 
Mild Moderate 
Severe with 
Insomnia 
Severe with 
Increased 
Appetite  
Symptom 
Resolution 
Mild with 
Insomnia Moderate 
Severe with 
Insomnia 
Latent Status Prevalences      
 0.28 0.25 0.30 0.18  0.61 0.24 0.10 0.06 
Item-Response Probabilities of QIDS-SR16 Indicators      
Sleep onset 
insomnia 0.56 0.49 0.87 0.30 
 
0.11 0.56 0.38 0.89 
Mid-nocturnal 
insomnia 0.73 0.57 0.83 0.69 
 
0.47 0.77 0.63 0.89 
Early morning 
insomnia 0.41 0.24 0.72 0.51 
 
0.07 0.48 0.18 0.74 
Hypersomnia 0.04 0.23 0.08 0.23  0.06 0.04 0.32 0.13 
Sad mood 0.63 0.85 0.95 0.94  0.04 0.27 0.60 0.95 
Decreased appetite 0.06 0.22 0.49 0.00  0.01 0.07 0.04 0.38 
Increased appetite 0.08 0.00 0.00 0.78  0.03 0.08 0.25 0.11 
Decreased weight 0.06 0.09 0.28 0.00  0.01 0.07 0.03 0.06 
Increased weight 0.06 0.01 0.03 0.42  0.03 0.07 0.08 0.10 
Impaired 
concentration 0.23 0.66 0.78 0.74 
 
0.02 0.19 0.52 0.93 
Negative self-view 0.24 0.57 0.68 0.63  0.03 0.22 0.45 0.72 
Suicidal ideation 0.09 0.08 0.18 0.12  0.01 0.06 0.12 0.18 
Lack of general 
interest 0.22 0.69 0.77 0.71 
 
0.05 0.23 0.55 0.70 
Fatigue 0.35 0.81 0.84 0.88  0.04 0.25 0.72 0.80 
Psychomotor 
retardation 0.09 0.30 0.54 0.46 
 
0.00 0.13 0.35 0.54 
Psychomotor 
agitation 0.19 0.20 0.54 0.26 
 
0.02 0.27 0.18 0.53 
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CHAPTER IV 
FUNCTIONAL IMPAIRMENT AND CHANGES IN DEPRESSION SUBTYPES 
FOR WOMEN IN STAR*D - A LATENT TRANSITION ANALYSIS 
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Abstract 
Objective: To characterize the association between functional impairment and major 
depression subgroups at baseline and to characterize changes in depression subgroups by 
level of functional impairment in women receiving citalopram in the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) trial. 
Method: We identified 755 women who completed baseline and week 12 study visits in 
level 1 of STAR*D. Indicators used to define the latent depression subgroups were self-
reported Quick Inventory of Depressive Symptomatology. The Work and Social 
Adjustment Scale was used to classify women as having normal/significant or major 
functional impairment at baseline. A latent transition analysis model with level of 
functional impairment used as a grouping variable provided estimates of the prevalence 
of latent depression status membership and transition probabilities. 
Results: Sixty-nine percent of women were classified as having major functional 
impairment at baseline. Four-status LTA models of latent depression statuses fit the data 
best. Regardless of functional impairment level, the depression statuses were 
differentiated by severity, appetite changes, psychomotor disturbances, and insomnia. 
Sixty-seven percent of women with major impairment belonged to severe depression 
statuses at baseline and 5% at week 12.  Among women with normal/significant 
functional impairments, 37% belonged to a severe depression at baseline nit no one 
belonged to such a status at week 12. Regardless of functional impairment level, the 
majority of women were likely to transition to a Symptom Resolution status at week 12 
(67% of women with normal/significant functional impairment; 60% of women with 
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major impairment). Women with baseline major impairment who were in the Severe with 
Psychomotor Agitation at the beginning of the study were least likely to transition to the 
Symptom Resolution status (4% chance).  
Conclusions: Level of functional impairment was related to both the kind of depression 
and the likelihood of moving to a different depression status for women treated with 
citalopram in level of 1 of STAR*D. These results underscore the need to incorporate not 
only depression symptoms but also functioning in the assessment and treatment of major 
depression. 
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Introduction 
Major depression is the second leading cause of disability worldwide101 and is 
associated with impairments in daily functioning and quality of life. In 2012, more than 
10 million adults in the U.S. had at least one major depressive episode with severe 
impairment in the past year.17 The extent of functional impairment seen with depression 
often exceeds that which is associated with many other common illnesses.102 Depression 
has the greatest impact on total work impairment of any chronic health disorder.103 This 
includes effects on lifetime employment opportunities due to lower education levels, 
productivity, presenteeism, absenteeism, and accidents.104 Almost 80% of people with 
major depression in the previous year have reported at least some interference with their 
ability to function with work.105  
Despite the profound impact of major depression on functional status, clinical 
trials of major depression rarely consider improvements in functioning as part of 
treatment success.106 Remission in trials is usually defined as reaching a specified score 
as determined by symptom rating scales and response is generally defined as 
experiencing a certain decrease in symptom rating score. When functioning is 
incorporated in trial designs, it typically is considered as a secondary outcome.  As such, 
studies may not be powered to detected differences in improvements in functional status. 
This lack of emphasis of improved functional status in clinical studies of major 
depression seems paradoxical for several reasons. First, it occurs despite the inclusion of 
impaired functioning in the diagnostic criteria for major depression.59 Second, depression 
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treatment guidelines recommend assessment of functional impairment. Lastly, treatment  
guidelines encourage interventions to target improved functioning.107  
The reliance on symptom ratings to assess improvements in depression is 
problematic as it may fail to capture changes in functional impairment. Discordance often 
exists between patients’ symptoms and their level of functioning.106,108 This discordance 
is not unidirectional. Some people with major depression symptoms rated as 
mild/moderate can have major deficits in functioning. Conversely, others might have 
severe symptoms but are able to function normally.109 In one study of people who were 
being treated for major depression, half of those with residual depression symptoms but 
who reported normal functioning considered themselves to be in remission from their 
depression.108 Obtaining remission as defined in most studies does not guarantee normal 
functioning.  Subthreshold depression symptoms are associated with functional 
impairment.102 This is particularly concerning because most people who achieve 
remission when treated for depression still experience residual symptoms.44  
Women and men experience certain aspects of depression differently and these 
differences appear to extend to functioning. Not only do women with major depression 
experience greater depression severity than men but women also have a greater burden of 
depressive disorders when compared to men.101,110 More women than men experience a 
major depressive episode with severe impairment, e.g., the episode severely impacts their 
ability to function in the domains of home management, work, close relationships with 
others, and/or social life.17 Women and men also seem to differ in the roles in which 
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functioning is impaired, with women experiencing more physical limitations and men 
having impaired social relationships.24  
While it has been seen that the functional impairment associated with major 
depression is more pronounced in women, there is a dearth of information about how 
transitions between depression subtypes during treatment may be different as a function 
of baseline functional impairment.  Better understanding of the association between 
functional impairment and transitions in depression subtypes could influence 
treatment.102,111 Latent transition analysis allows us to explore differences in latent 
depression statuses by level of functional impairment, including changes in these 
depression statuses after antidepressant treatment. 
The overall objective of this study was to examine differences in functional 
impairment in latent statuses of depression in women participating in level 1 of STAR*D. 
Specifically, the aims were to 1) characterize the association between functional 
impairment and major depression subgroups at baseline; and 2) characterize changes in 
depression subgroups by level of baseline impairment at the end of 12 weeks of 
citalopram treatment. 
Methods 
Study Participants 
 This analysis used the limited use, de-identified dataset of participants from level 
1 of STAR*D. This dataset is publicly available from the National Institute of Mental 
Health (NIMH). STAR*D was a large pragmatic clinical trial originally designed to 
evaluate the effectiveness of different pharmacological and psychosocial treatments for 
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real world patients with moderate to severe non-psychotic major depression.42 Eighteen 
primary care and 23 outpatient psychiatric sites enrolled 4,041 participants who were 
seeking depression treatment from July 2001-April 2004. Participants in level 1 all 
received citalopram for up to 14 weeks. After enrollment, study visits were conducted at 
2, 4, 6, 9, and 12 weeks with an optional visit at week 14. Of the evaluable sample of 
2,876 participants who had a score greater than or equal to 14 on the Hamilton Rating 
Scale of Depression (HRSD) and who completed at least one post-baseline visit, 28% 
achieved remission as defined by an HRSD score less than or equal to 7. Thirty-three 
percent of participants achieved remission when it was defined as an observed self-report 
Quick Inventory of Depressive Symptomatology (QIDS-SR16) score less than or equal to 
5.33 Approximately 47% of the evaluable sample participants achieved response as 
defined by at least a 50% reduction in baseline QIDS-SR score. STAR*D has been 
described in further detail elsewhere.112  
 Because our overall goal was to examine how functional impairment is related to 
transitions in depression subgroups over the 12-week treatment period, participants could 
not be missing all QIDS-SR16 items at baseline and week 12 or the Work and Social 
Adjustment Scale (WSAS) at baseline to be eligible for this study (n = 755).
 STAR*D participants provided written informed consent after receiving a 
complete description of the study at enrollment. The protocol was originally approved 
and monitored by the institutional review boards at the trial’s national coordinating 
center, the data coordinating center, clinical sites, and the NIMH Data, Safety, and 
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Monitoring Board. The institutional review board at the University of Massachusetts 
Medical School determined that this secondary analysis was not human subject research. 
Measures 
Indicators of Latent Status Membership 
 The 16 individual QIDS-SR16 items collected at baseline and week 12 were used 
as the observed indicators of latent depression status. The QIDS-SR16 measures overall 
depression severity and the items correspond to the nine DSM-IV criterion symptoms for 
major depressive disorder.46 Although the QIDS-SR16 instructions specify that only one 
item on appetite increase or decrease and weight increase or decrease should be 
completed, we included these items as four separate indicator variables to capture the 
direction of appetite and weight changes. Each item except those pertaining to weight 
changes reflects the previous seven days. The increased and decreased weight items 
inquire about changes in the last 14 days. The score for each item ranges from 0-3, with a 
score  2 reflecting that the symptom meets the DSM-IV threshold for the presence of a 
criterion symptom. Accordingly, for this analysis, the items were dichotomized so that a 
score ≤ 1 indicated the absence of a criterion symptom while a score ≥ 2 indicated the 
presence of a criterion symptom.44  
Functional Impairment 
Depression-specific functional impairment was measured with the Work and 
Social Adjustment Scale (WSAS). The WSAS is a 5-item self-report scale assessing 
work, home management, social activities, private leisure activities, and close 
relationships.113 STAR*D participants completed the WSAS via interactive voice 
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response system (IVR) calls at baseline, week 6, and week 12/study exit. Participants 
were asked to rate how much their depression specifically impaired these domains. Each 
item is scored from 0 (no impairment) to 8 (very severe impairment). WSAS total scores 
greater than 20 indicate major impairment, scores of 10-20 represent significant 
functional impairment, and scores less than 10 are considered to be within normal ranges 
of functioning. Only 5% of women had a baseline WSAS score of 0-9 so WSAS scores 
were dichotomized as normal/significant functional impairment (WSAS = 0-20) and 
major functional impairment (WSAS  21).  
Analysis 
The statistical analysis was conducted in two parts: 1) characterizing the 
sociodemographic and clinical characteristics of the overall sample by level of baseline 
functional impairment; and 2) evaluating differences in latent depression statuses 
throughout treatment by level of baseline functional impairment. First, we calculated 
descriptive statistics to compare demographic and clinical characteristics of the women 
categorized as having major functional impairment or normal/significant functional 
impairment. Since small differences were likely to achieve statistical significance due to 
the sample size, we considered only absolute differences  5% in the prevalence 
estimates between the functional impairment groups to be notable.  
In the second part of our analysis, the association of baseline functional 
impairment and depression subgroup was examined by fitting LTA models with 
categorical WSAS scores as a grouping variable. Models with all parameters freed to 
vary and the number of statuses ranging from two to seven were fit first. The selection of 
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the optimal number of statuses was informed by the interpretability of each status and fit 
statistics such as Akaike Information Criterion (AIC) and Bayesian Information Criterion 
(BIC). The relative fit and parsimony of the models was emphasized in addition to the 
formal fit statistics because LTA models can have very large degrees of freedom and 
extreme sparseness, which can skew the fit statistics.34 Models where measurement 
invariance was imposed on the item-response probabilities between groups and over time 
were then explored to see if the depression statuses differed by level of functional 
impairment. Measurement invariance was formally tested using the G2 difference test to 
compare several nested models: 1) models where all parameters were allowed to vary 
between functional impairment group and from baseline to week 12; 2) models where the 
parameters were constrained to be equal between the two functional impairment groups 
but were allowed to vary over time; and 3) models in which the parameters were 
constrained to be equal between the functional impairment groups and at baseline and 
week 12.34 Models 2 and 3 were compared to model 1 using separate G2 difference tests. 
In this second phase, we used one LTA model to see if the qualitative nature of the latent 
depression statuses were different between the baseline impairment level and to see how 
the transitions in status membership were different for each impairment group.  As we 
constructed the LTA model, we were able to constrain some of the item-response 
probabilities to reduce sources of heterogeneity and improve the interpretability of the 
model.  Analyses were conducted using PROC LTA53,88 in SAS 9.3 (SAS Institute, Inc., 
Cary, NC). 
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Results 
Sixty-nine percent of women had major functional impairment at baseline as 
measured by the WSAS. Women with major functional impairment at baseline were 
more likely than women with normal/significant impairment to be younger at depression 
onset, to have severe depression, and to have lower physical and mental functioning 
scores, and to have lower quality of life enjoyment and satisfaction (Table 4.1). Both 
groups had high rates of having a psychiatric comorbidity but women with major 
functional impairment were more likely to have GAD, PTSD, bulimia, social phobia, 
psychosis, agoraphobia, and drug abuse/dependence. At the beginning of STAR*D, the 
majority of both groups of women were likely to be experiencing sleep-onset insomnia, 
mid-nocturnal insomnia, sad mood, and fatigue (Table 4.2).  The women with major 
impairment were more likely to have sleep-onset insomnia, sad mood, decreased appetite, 
weight changes, impaired concentration, negative self-view, lack of general interest, 
fatigue, psychomotor retardation, and psychomotor agitation.  
When functional impairment was considered as a grouping variable in the LTA 
models, a four-status model fit the data best (Supplementary Table 4.1). Formal G2 
difference tests indicated that measurement invariance for all statuses across the 
impairment groups (𝐺2
2-𝐺1
2 =171.34, df = 128, p = 0.006) or across groups and time could 
not be assumed (𝐺2
2-𝐺1
2 =355.28, df = 192, p <0.0001). After careful consideration of the 
item-response probabilities of the indicator variables that produce the description of each 
status, however, measurement invariance was imposed on several latent statuses due to 
qualitative similarities: the Moderate statuses at baseline and week 12 for women in the 
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normal/significant and major impairment groups; the Severe with Increased Appetite 
statuses at baseline for women in both impairment groups; the Symptom Resolution 
statuses at week 12 for both impairment groups; and the Insomnias Only statuses at week 
12 for both impairment groups (Table 4.3). Imposing measurement invariance in this way 
is desirable in aiding model fitting and enhancing the interpretability of the statuses. 
For the women in the normal/significant impairment group, the statuses at 
baseline were Mild Depression, Moderate Depression, Severe Depression with Increased 
Appetite, and Severe Depression with Insomnias (Table 4.3). The statuses at week 12 
were Symptom Resolution, Mid-Nocturnal Insomnia Only, All Insomnias Only, and 
Moderate Depression. Mid-nocturnal insomnia and sad mood were the only symptoms 
highly likely to be endorsed in every status at baseline whereas only sleep-onset insomnia 
was likely to be endorsed by women in all the statuses at week 12 except for those in the 
Symptom Resolution status. At baseline, the Mild, Moderate, and Severe with Insomnias 
statuses were almost all equally most prevalent, with 31-32% of women likely to belong 
to these statuses (Figure 4.1). With a prevalence of 5%, Severe with Increased Appetite 
was the least prevalent at baseline. The majority of women (67%) were likely to be in the 
Symptom Resolution status after treatment. The fewest women (8%) were likely to 
belong to the Moderate status. Women in the Moderate status at baseline moved to the 
Symptom Resolution status at week 12. The women in the Severe with Insomnias status 
were the least likely to move to the Symptom Resolution status (32% chance). These 
women were more likely to transition to the All Insomnias Only status (34% chance). 
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For the women with major functional impairment, the statuses at baseline were 
Moderate Depression, Severe Depression with Decreased Appetite, Severe Depression 
with Increased Appetite, and Severe Depression with Psychomotor Agitation (Table 4.3). 
The statuses at week 12 were Symptom Resolution, Depression with All Insomnias Only, 
Moderate Depression, and Severe Depression with Psychomotor Disturbances. Women in 
all statuses were likely to be experiencing mid-nocturnal insomnia, sad mood, and fatigue 
at baseline. Sleep-onset insomnia and mid-nocturnal insomnia were likely to be endorsed 
by all statuses except Symptom Resolution at week 12. The Severe with Decreased 
Appetite status was the most common at baseline, with a prevalence of 36% (Figure 4.2). 
At 12% of women, the Severe with Psychomotor Agitation status was the least prevalent. 
These women had the lowest chance of transitioning to the Symptom Resolution status at 
week 12 (4%) and were most likely to move to the All Insomnias Only status (62% 
chance). Those in the Moderate status had the greatest chance (86%) of transitioning to 
the Symptom Resolution status. The majority of women were likely to belong to the 
Symptom Resolution status (60%) at week 12 while only 5% were likely to be in Severe 
with Psychomotor Disturbances. Women in the statuses distinguished by appetite 
changes were the only ones with a chance of transitioning to Severe with Psychomotor 
Disturbances, the only status not distinguished by having fewer prominent symptoms, at 
13% and 5%, respectively. 
Discussion 
 The overall goal of this study was to explore how latent depression statuses differ 
by baseline functional impairment and to describe how the qualitative nature of these 
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depression statuses differed by baseline level of functional impairment for women being 
treated with citalopram. Using level of functional impairment in a multiple-group LTA 
model demonstrated that depression types for women in STAR*D differed by level of 
impairment and that baseline impairment influenced changes in depression type during 
citalopram treatment. Women with major functional impairment at baseline had more 
Severe Depression statuses at both time points when compared to women with 
normal/significant functional impairment. This is expected since greater depressive 
symptom severity was seen to be correlated with lower functioning in a previous analysis 
of a subset of men and women participating in STAR*D.114 
The types of depression experienced by women in both functional impairment 
groups were similar in a few ways but the statuses for those with major impairment were 
characterized by more severe depression throughout the study. The Moderate, Severe 
with Increased Appetite, Symptom Resolution, and All Insomnias Only statuses were 
common to both groups but the women who started level 1 of STAR*D with major 
functional impairment had more Severe depression statuses at both times. The Severe 
statuses for these women were marked by prominent symptoms related to decreased and 
increased appetite and psychomotor disturbances. The women with normal/significant 
impairment had Severe statuses distinguished by increased appetite and insomnias and 
these Severe statuses were only present at baseline. Beyond differences in the descriptive 
nature of the Severe statuses, the prevalences of these statuses also differed by functional 
impairment group, with more than three times as many women with major impairment 
likely to be in the Severe with Increased Appetite baseline than in the mild/significant 
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functional impairment group. Women with baseline major impairment also had lower 
probabilities of transitioning to a status differentiated by endorsing fewer symptoms 
when compared to women with baseline normal/significant impairment. 
It is not surprising that the latent depression statuses for women with major 
functional impairment would be characterized by the endorsement of more depression 
symptoms than those of the women with normal/significant functional impairment since 
greater depression symptom severity has been seen to be related to reduced quality of life 
and functioning in all STAR*D participants.115,116 Additionally, women with major 
functional impairment in this analysis had more comorbid anxiety disorders than women 
with normal/significant impairment and comorbid anxiety disorders appear to increase 
the risk of low health-related quality of life across numerous domains for women.117 
Rates of improvement in quality of life are lower for people with chronic major 
depression and those with comorbid psychiatric disorders. Furthermore, specific anxiety 
disorders may differentially impact domains of functioning, e.g., social phobia would 
impair social functioning,111 but examining individual psychiatric comorbidities was 
beyond the scope of this analysis. 
Both groups of women experienced depression statuses distinguished by 
combinations of insomnia symptoms at both baseline and week 12. Almost a third of the 
women with normal/significant impairment were in the Severe with Insomnias status at 
baseline. These women had the lowest chances of transitioning to the Symptom 
Resolution status after treatment. While the women with major impairment did not have a 
baseline depression status distinguished by insomnia, almost a quarter of them had 
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moved into the All Insomnias Only status at week 12. The prominence of insomnia is in 
line with the associations between insomnia, sleepiness, fatigue and functioning in 
depression.102,109 These insomnia symptoms likely warrant further attention in treatment 
approaches for depression since they are common residual symptoms44 and treatment side 
effects. Insomnia also increases risk of depression recurrence57,65 and lack of treatment 
response.66 
Our results should be interpreted in the context of several limitations. This was a 
post-hoc analysis of clinical trial data that were not originally collected for such subgroup 
analyses. These LTA models were unable to address all of the known correlates of 
reduced functioning in depression because of issues of model convergence when trying to 
fit complex latent variable models. Age, race, education, marital status, employment 
status, medical comorbidities, and health insurance coverage have been observed to be 
related to baseline functioning in a separate subsample of STAR*D participants.114 This 
analysis also only examined functioning as captured by the WSAS, which does not cover 
all domains of health-related quality of life. Furthermore, 21 women were excluded from 
this analysis because they did not complete the IVR call during which the functioning 
assessments were completed and these women might differ on level of functioning 
compared to the women who were able to complete the call. Lastly, this analysis focused 
only on functional impairment observed at baseline. It may be important to consider 
functioning longitudinally since improvements in functioning have been demonstrated 
with antidepressant treatment and such improvements can lag behind symptom 
improvements.118 
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 Despite these limitations, our analysis is noteworthy for several reasons. This is 
one of the first analyses to use LTA to examine how functional impairment is related to 
depression subtypes and changes in these subtypes following antidepressant treatment. 
LTA allowed us to efficiently discern depression subtypes among women during a 
clinical trial and to examine the association between functional impairment and changes 
in depression symptoms following treatment with citalopram. Although data sparseness 
limited our ability to examine some factors of potential interest, this is still one of the 
largest samples to which LTA has been applied. While methods for power calculations in 
LTA are still being developed, it has been suggested that sample sizes of 300 people or 
more are sufficient.119 Although STAR*D enrolled treatment-seeking outpatients and 
thus our results have limited generalizability, it is still the largest and longest depression 
treatment study and is considered more representative of people with depression who are 
seen outside of idealized research setting than most trials. 
 Our results highlight the importance of looking beyond summary rating scores of 
depression symptoms when studying depression heterogeneity during treatment.  For 
women in STAR*D, level of functional impairment was related to the likelihood of 
moving to a depression status differentiated by endorsing fewer symptoms and thus 
treatment strategies may want to consider not only symptom severity but also degree of 
functional impairment. Assessment and treatment of major depression should not focus 
exclusively on symptoms but also incorporate domains of functioning. Doing so could 
reduce the substantial disability and burden associated with depression.  
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Table 4.1: Baseline demographic and clinical characteristics of women participating in 
STAR*D level 1 by baseline functional impairment 
Characteristic 
Normal/significant 
functional 
impairment
1
 
(n = 231) 
Major functional 
impairment
2
 
(n = 524) p-value 
Age at study entry, mean (SD) 42.5 (14.1) 41.0 (12.7) 0.141 
45 years of age or older at study 
entry, n (%) 
100 (43.3) 215 (41.0) 0.562 
Age at onset, mean (SD) 27.5 (15.5) 23.6 (14.0) <0.001 
Race, n (%)    
White 184 (79.7) 397 (75.8) 0.227 
Black or African American 28 (12.1) 89 (17.0)  
Other 19 (8.2) 38 (7.3)  
Hispanic, n (%) 33 (14.3) 70 (13.4) 0.732 
Number of depressive episodes 
before baseline, mean (SD) 
4.3 (6.7) 4.6 (6.3) 0.581 
Depression severity (QIDS-SR16), 
mean (SD) 
13.6 (3.7) 17.2 (3.6) <0.001 
SF-12 PCS total score,3 mean (SD) 52.6 (10.8) 48.4 (12.0) <0.001 
SF-12 MCS total score,4 mean (SD) 28.8 (8.7) 24.0 (7.1) <0.001 
Q-LES-Q total score,5 mean (SD) 50.8 (11.6) 36.8 (12.3) <0.001 
Psychiatric comorbidity, n (%)     
Any psychiatric comorbidity 115 (49.8) 349 (66.6) <0.001 
Generalized anxiety disorder 30 (13.1) 141 (27.2) <0.001 
Post-traumatic stress disorder 17 (7.5) 98 (19.1) <0.001 
Bulimia 28 (12.2) 94 (18.2) 0.042 
Social phobia 45 (20.0) 166 (32.2) <0.001 
OCD 13 (5.7) 49 (9.5) 0.084 
Panic disorder 13 (5.7) 76 (14.6) <0.001 
Psychosis 17 (7.4) 70 (13.5) 0.017 
Agoraphobia 9 (4.0) 66 (12.9) <0.001 
Alcohol abuse/dependence 18 (7.9) 47 (9.0) 0.600 
Drug abuse/dependence 3 (1.3) 31 (6.0) 0.005 
Somatization disorder 3 (1.3) 16 (3.1) 0.154 
Hypochondriasis 10 (4.4) 21 (4.1) 0.843 
1Normal/significant functional impairment = WSAS total score ≤ 20 at baseline.  
2Major functional impairment = WSAS total score ≥ 21 at baseline. 
3Short Form-12 Health Survey Physical Component Summary. A higher score indicates better functioning. 
4Short Form-12 Health Survey Mental Component Summary. A higher score indicates better functioning. 
5Quality of Life Enjoyment and Satisfaction Questionnaire. A higher score indicates better quality of life.  
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Table 4.2: Frequency of baseline QIDS-SR16 indicators by baseline functional 
impairment for women participating in STAR*D level 1 
QIDS-SR16 item 
Normal/ 
significant 
functional 
impairment
1
 
(n = 231) 
N (%) 
Major  
functional 
impairment
2
 
(n = 524) 
N (%) p-value 
Sleep-onset insomnia 134 (58.0) 354 (67.6) 0.011 
Mid-nocturnal insomnia 162 (70.1) 379 (72.3) 0.537 
Early morning insomnia 100 (43.3) 265 (50.6) 0.065 
Hypersomnia 26 (11.3) 88 (16.8) 0.050 
Sad mood 169 (73.2) 472 (90.1) <0.001 
Decreased appetite 35 (15.2) 130 (24.8) 0.003 
Increased appetite 35 (15.2) 111 (21.2) 0.053 
Decreased weight 18 (7.8) 71 (13.6) 0.024 
Increased weight 15 (6.5) 77 (14.7) 0.002 
Impaired concentration 89 (38.5) 365 (69.7) <0.001 
Negative self-view 95 (41.1) 322 (61.5) <0.001 
Suicidal ideation 21 (9.1) 63 (12.0) 0.238 
Lack of general interest 91 (39.4) 353 (67.4) <0.001 
Fatigue 131 (56.7) 432 (82.4) <0.001 
Psychomotor retardation 43 (18.6) 220 (42.0) <0.001 
Psychomotor agitation 54 (23.4) 167 (31.9) 0.018 
1Normal/significant functional impairment = WSAS total score ≤ 20 at baseline.  
2Major functional impairment = WSAS total score ≥ 21 at baseline. 
 
 
 
 
Table 4.3: Item-response probabilities from a four-status LTA of QIDS-SR16 indicators with baseline functional impairment as 
a grouping variable1  
Normal/Significant Functional Impairment at Baseline
2
 (n = 231) 
 Baseline Latent Statuses  Week 12 Latent Statuses 
QIDS-SR16 items Mild Moderate 
Severe with 
Increased 
Appetite 
Severe with 
Insomnias  
Symptom 
Resolution 
Mid-Nocturnal 
Insomnia Only 
All 
Insomnias 
Only Moderate 
Sleep onset 
insomnia 0.41 0.45 0.63 0.81 
 
0.12 0.23 0.59 0.45 
Mid-nocturnal 
insomnia 0.78 0.59 0.69 0.77 
 
0.46 1.00 0.76 0.59 
Early morning 
insomnia 0.39 0.28 0.53 0.65 
 
0.05 0.40 0.50 0.28 
Hypersomnia 0.00 0.22 0.27 0.08  0.06 0.00 0.05 0.22 
Sad mood 0.53 0.74 0.99 0.89  0.04 0.00 0.26 0.74 
Decreased appetite 0.03 0.10 0.00 0.37  0.01 0.05 0.08 0.10 
Increased appetite 0.07 0.14 0.85 0.10  0.03 0.02 0.10 0.14 
Decreased weight 0.00 0.05 0.00 0.18  0.01 0.08 0.07 0.05 
Increased weight 0.05 0.05 0.54 0.01  0.01 0.31 0.07 0.05 
Impaired 
concentration 0.07 0.53 0.78 0.49 
 
0.02 0.00 0.24 0.53 
Negative self-view 0.14 0.43 0.73 0.64  0.03 0.05 0.24 0.43 
Suicidal ideation 0.05 0.07 0.13 0.17  0.01 0.00 0.07 0.07 
Lack of general 
interest 0.09 0.50 0.83 0.57 
 
0.06 0.00 0.28 0.50 
Fatigue 0.28 0.72 0.92 0.62  0.06 0.00 0.31 0.72 
Psychomotor 
retardation 0.00 0.24 0.56 0.30 
 
0.00 0.03 0.18 0.24 
Psychomotor 
agitation 0.09 0.15 0.25 0.45 
 
0.02 0.00 0.30 0.15 
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Major Functional Impairment at Baseline
3
 (n = 524) 
 Baseline Latent Statuses  Week 12 Latent Statuses 
QIDS-SR16 
items Moderate 
Severe with 
Decreased 
Appetite 
Severe with 
Increased 
Appetite 
Severe with 
Psychomotor 
Agitation  
Symptom 
Resolution 
All 
Insomnias 
Only Moderate 
Severe with 
Psychomotor 
Disturbances 
Sleep onset 
insomnia 0.45 0.82 0.63 1.00 
 
0.12 0.59 0.45 0.67 
Mid-nocturnal 
insomnia 0.59 0.81 0.69 0.83 
 
0.46 0.76 0.59 0.82 
Early morning 
insomnia 0.28 0.61 0.53 0.72 
 
0.05 0.50 0.28 0.53 
Hypersomnia 0.22 0.14 0.27 0.00  0.06 0.05 0.22 0.24 
Sad mood 0.74 0.96 0.99 0.95  0.04 0.26 0.74 0.94 
Decreased 
appetite 0.10 0.54 0.00 0.14 
 
0.01 0.08 0.10 0.15 
Increased 
appetite 0.14 0.00 0.85 0.09 
 
0.03 0.10 0.14 0.25 
Decreased 
weight 0.05 0.31 0.00 0.06 
 
0.01 0.07 0.05 0.07 
Increased weight 0.05 0.04 0.54 0.12  0.01 0.07 0.05 0.15 
Impaired 
concentration 0.53 0.85 0.78 0.50 
 
0.02 0.24 0.53 0.92 
Negative self-
view 0.43 0.75 0.73 0.47 
 
0.03 0.24 0.43 1.00 
Suicidal ideation 0.07 0.17 0.13 0.09  0.01 0.07 0.07 0.28 
Lack of general 
interest 0.50 0.88 0.83 0.31 
 
0.06 0.28 0.50 0.85 
Fatigue 0.72 0.93 0.92 0.65  0.06 0.31 0.72 0.97 
Psychomotor 
retardation 0.24 0.56 0.56 0.23 
 
0.00 0.18 0.24 0.70 
Psychomotor 
agitation 0.15 0.44 0.25 0.55 
 
0.02 0.30 0.15 0.51 
1Measurement invariance was imposed on the item-response probabilities describing the Moderate statuses; the Severe with Increased Appetite statuses; 
the Symptom Resolution statuses; and the Insomnias Only statuses. 
2Normal/significant functional impairment = WSAS total score ≤ 20 at baseline.  
3Major functional impairment = WSAS total score ≥ 21 at baseline. 
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CHAPTER V 
 DISCUSSION AND CONCLUSIONS 
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The overall purpose of this dissertation was to examine latent variable methods 
for understanding heterogeneity in major depression. Major depression is based on a 
phenomenological diagnosis and is associated with extensive variability in etiology, risk 
factors, and symptom profiles. Despite more than five decades of antidepressant 
development, medications and psychotherapies fail to help a considerable amount of 
people with depression.120 While a substantial amount of previous research has tried to 
address this heterogeneity with subgroup analyses and various depression subtypes have 
been proposed, the longitudinal stability of subgroups is rarely evaluated and debate still 
exists regarding how to successfully treat most people with depression. 
  Although much still needs to be learned about the pathophysiological 
mechanisms of the brain responsible for depression,121 the limitations of traditional 
methods for subgroup analyses might also be hindering progress towards precision 
medicine for major depression and other serious mental illnesses. These limitations 
include the issue of high Type I error due to multiple comparisons and lack of adequate 
sample sizes and power to detect effects across subgroups or to examine higher-order 
interactions in subgroups.35 The work of this dissertation shows that latent class analysis 
(LCA) and latent transition analysis (LTA) are valuable alternative methods for 
elucidating depression subtypes based on the many possible patterns of depression 
symptoms and for examining changes in these symptom patterns after antidepressant 
treatment in level 1 of STAR*D. Conclusions from the three specific aims of this 
dissertations and implications for future work in this area are summarized below. 
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Differences in Latent Depression Subtypes between Men and Women 
  When latent class analysis was conducted at baseline in Aim 1 (Chapter II), four 
latent classes of depression were ultimately identified that were consistent for men and 
women. Men and women experienced the same patterns of depression symptoms but the 
proportions of men and women likely to be in the Mild Depression, Severe Depression 
with Increased Appetite, and Severe Depression with Insomnia classes differed. More 
women were likely to belong to the Severe with Insomnia class than any other class but 
the most prevalent class for men was the Mild Depression class. The difference between 
the prevalence of men and women in the Severe with Increased Appetite class prevalence 
was remarkable, with almost twice as many women in this class. The associations 
between comorbid anxiety disorders and the odds of membership in each latent class 
were similar for men and women. 
 While the qualitative nature of the depression subtypes were the same for men 
and women when only baseline data was examined, the latent transition analyses 
performed in Aim 2 (Chapter III) demonstrated that the types of depression experienced 
by men and women differed when both baseline and week 12 symptoms were included. 
The latent depression statuses for both men and women were distinguished primarily by 
severity but psychomotor agitation and retardation further differentiated men’s latent 
depression statuses. Appetite changes, insomnia, and psychomotor disturbances 
characterized statuses for women. After 12 weeks of citalopram treatment, transition to 
Symptom ResolutionMen was most likely for men in the MildMen status at baseline but 
least likely for Men in the Severe Depression with Psychomotor Agitation status. Among 
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women, those in the ModerateWomen status had the greatest chance of moving to Symptom 
ResolutionWomen while those in the Severe with Decreased Appetite status had the lowest 
chance of transitioning to Symptom ResolutionWomen. 
 The differences between patterns of depression symptoms and changes in these 
patterns experienced by men and women revealed here emphasize the need to consider 
the influence on sex and gender when studying and treating depression. 122 Disparities in 
rates, severity, and course of depression between men and women have previously been 
observed but the extent to which these differences are due to sex influences (e.g., 
women’s hormone changes precipitating insomnia) or to gender influences (e.g., women 
being more likely to seek depression treatment) remains unclear.  
The Role of Comorbid Psychiatric Disorders 
 Comorbid psychiatric disorders, especially anxiety disorders, were related to 
latent depression subgroups in both LCA and LTA models.  In Aim I (Chapter II), 
comorbid GAD, bulimia, and social phobia were related to increased odds of membership 
in the Severe Depression with the Increased Appetite class at baseline. GAD, PTSD, and 
social phobia were associated with the Severe Depression with Insomnia class. It was 
seen in Aim 3 (Chapter IV) that women with baseline major functional impairment were 
more likely than women with normal/significant impairment to have a psychiatric 
comorbidity. Low prevalences of some disorders in this sample and missing data reduced 
our ability to examine some individual psychiatric comorbidities in the LCA and LTA 
models. 
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 Comorbidity rates between depression and anxiety are generally very high, with 
75% of people with a current depressive disorder having a lifetime comorbid anxiety 
disorder and 67% having a current anxiety disorder.123 The presence of anxiety with 
depression is also associated with lower odds of remission during treatment and with 
delayed treatment response.124 Given this, the apparent influence of psychiatric 
comorbidities on depression in this dissertation work is not surprising. What remains 
unknown, however, is the role of these comorbidities in changes in depression subtypes 
over time.  A latent transition analysis examining individual comorbidities in predicting 
latent depression statuses at baseline and predicting transitions in statuses throughout 
treatment would be valuable. 
Functional Impairment and Depression Subtypes for Women 
 Examining LTA models by functional impairment in Aim 3 (Chapter IV) showed 
that the degree of functional impairment experienced by women at baseline was related to 
both depression subtypes at baseline and the chances of transitioning to a different 
depression status at week 12. Almost all women started level 1 of STAR*D with some 
degree of functional impairment, as assessed by the Work and Social Adjustment Scale. 
The majority of these women were experiencing major functional impairment at baseline. 
The multiple-groups LTA model, which is similar to performing stratification in non-
latent variable analyses, indicated that some depression statuses differed between the 
women with baseline major impairment and the women with normal/significant 
impairment. In particular, unlike those with normal/significant impairment, the women 
with major functional impairment could belong to statuses at baseline and week 12 that 
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were distinguished by psychomotor disturbances. The majority of women in both 
baseline functional impairment groups were likely to transition to the Symptom 
Resolution status at week 12 but those with baseline major impairment who started in the 
Severe Depression with Psychomotor Agitation at the beginning of the study were least 
likely to transition to the Symptom Resolution status. 
 These results underscore the need to incorporate not only depression symptoms 
but also functioning in the assessment and treatment of major depression. Sample size 
issues restricted the LTA models to women and, although women with depression appear 
to have more functional impairment than men, it would be useful to replicate these 
analyses in a sample of men since men and women have been observed to experience 
impairments in different domains of functioning. Additionally, future research on how 
functional impairment changes during treatment and how it predicts transitions in 
depression subtypes is warranted. 
The Problem with Relying on Summary Rating Scores of Symptom Severity 
The results of this dissertation highlight the need to not collapse information 
about individual depression symptoms and rely solely on summary rating scores of 
symptom severity when studying and treating depression. Rates of response and 
remission have been seen to vary in the same population when cut-off scores on different 
rating scales are used to define treatment response and remission, making it difficult to 
know when patients are experiencing satisfactory relief from their depression.125 
Furthermore, when exploring predictors and moderators of treatment effects, it is 
important to consider domains beyond depression symptoms that were not available in 
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the data analyzed here, such as cognitive measures,126 that have potential to differentiate 
people who remit from those who do not. Doing so will become even more important as 
the National Institute of Mental Health emphasizes clinical trials that focus on the 
biological processes involved in a psychiatric disease and not only on ameliorating 
symptoms.127 Efforts to reduce the burden of depression should also incorporate measures 
of functional impairment in both predicting treatment effects and in defining response 
and remission so that successful treatment improves not just symptoms but overall quality 
of life. 
 This dissertation demonstrates the potential of LCA and LTA as approaches that 
can be used to characterize discrete changes among multiple aspects of a disease. Such 
approaches are particularly important in psychiatry, which is haunted by the absence of 
known pathophysiologic causes of disorders such as depression128 and where disorders 
are currently defined by heterogeneous symptoms which are likely not disease-specific. 
When the National Comorbidity Survey-Replication (NCS-R) considered 19 different 
possible DSM diagnoses, only 433 of the 524,288 logically possible disorder profiles 
were observed.2 Almost 80% of these observed profiles involved comorbid cases of three 
or more disorders. Determining specific features that can distinguish groups of people 
with depression that have differential responses to treatment could ultimately aid in 
clinical treatment decision-making and alleviate the burden of depression quicker than 
the current system of selecting the best treatment through trial and error.  The results 
presented here need to be replicated in other samples and for other treatments. Doing so 
could ultimately provide information about predicting treatment remission. 
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 Beyond improving subgroup detection to inform treatment response in major 
depression, LCA and LTA should be explored as analytic techniques for informing new 
approaches to classifying mental disorders. These person-centered statistical methods 
could be valuable for making sense of the myriad potential biological and psychosocial 
indicators of serious mental illnesses, as emphasized by the National Institute of Mental 
Health’s Research Domain Criteria initiative. 
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